<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="cedc4b34-5c83-4d5f-a47f-7d5e93f71459"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use APRETUDE safely and effectively. See full prescribing information for APRETUDE.<br/>
      <br/>APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use<br/>Initial U.S. Approval: 2021</title>
   <effectiveTime value="20250411"/>
   <setId root="4338428e-43d4-4e02-ac9d-bd98e738a7da"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="027295585" root="1.3.6.1.4.1.519.1"/>
            <name>ViiV Healthcare Company</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b3a2c70c-8f57-4a41-a61b-f9aa53b6e166"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20231213"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="49702-264" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Apretude</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cabotegravir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="49702-264-23" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="49702-238" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Cabotegravir</name>
                              <formCode code="C42926" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SUSPENSION, EXTENDED RELEASE"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Cabotegravir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="200"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="HMH0132Z1Q" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CABOTEGRAVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="HMH0132Z1Q" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>CABOTEGRAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="3"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="49702-238-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA215499" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <effectiveTime>
                                    <low value="20211220"/>
                                 </effectiveTime>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                                    <originalText>white to light pink</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215499" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20211220"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="49702-280" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Apretude</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cabotegravir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="49702-280-63" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240331"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="mL" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="49702-238" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Cabotegravir</name>
                              <formCode code="C42926" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SUSPENSION, EXTENDED RELEASE"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Cabotegravir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="200"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="HMH0132Z1Q" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CABOTEGRAVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="HMH0132Z1Q" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>CABOTEGRAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 20</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="3"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="49702-238-61" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA215499" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <effectiveTime>
                                    <low value="20211220"/>
                                 </effectiveTime>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240331"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                                    <originalText>white to light pink</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215499" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20211220"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_38582d99-95b5-4c0a-97fb-96af7940cd05">
               <id root="170e2f5e-eda0-4211-a1e2-35cb1d49c4a0"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <table styleCode="Noautorules" width="100%">
                           <col width="58%"/>
                           <col width="10%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions, Hypersensitivity Reactions (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>4/2025</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_fdd55230-c911-41c4-84dc-1975262d3c6d">
               <id root="d12a91d2-ace3-467d-87c0-927ad93b58a3"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE‑EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>), Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE for HIV-1 PrEP by individuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen. (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>, <linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>, <linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_23ec8e4c-20d4-4a81-ad10-29dfb92c6b7c">
               <id root="e2aa7f94-ce57-47b2-a1d0-3569ac9fa84a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>, <linkHtml href="#ID_e4568929-5251-4637-9e91-ddf7d4eb8285">2.4</linkHtml>), Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. (<linkHtml href="#ID_23ec8e4c-20d4-4a81-ad10-29dfb92c6b7c">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_540d4427-c48a-4605-9d73-59e258ac5ec6">
               <id root="7837ae41-13d1-4798-9da4-bac0830f05e6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>HIV-1 Screening: Screen all individuals for HIV-1 infection immediately prior to initiating APRETUDE for HIV-1 PrEP and prior to each injection while taking APRETUDE. (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Prior to initiating APRETUDE, an oral lead-in dosing may be used for approximately 1 month with the recommended dosage to assess the tolerability of APRETUDE. (<linkHtml href="#ID_e4568929-5251-4637-9e91-ddf7d4eb8285">2.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>For gluteal intramuscular injection only. (<linkHtml href="#ID_e156ceb9-623e-4679-bb58-8914f683b2f9">2.5</linkHtml>, <linkHtml href="#ID_debb9a3b-2f0e-4ddd-9073-822e600d3ae0">2.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Recommended Dosing Schedule: Initiate APRETUDE with a single 600-mg (3-mL) injection given 1 month apart for 2 consecutive months on the last day of an oral lead-in if used or within 3 days and continue with the injections every 2 months thereafter. (<linkHtml href="#ID_e156ceb9-623e-4679-bb58-8914f683b2f9">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1d87c661-c4a2-49ad-89fa-5eec92f51e27">
                     <id root="21c4a192-45b1-4df3-95cf-1604286ece64"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosage and Administration Overview </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>APRETUDE contains cabotegravir extended-release injectable suspension in a single-dose vial <content styleCode="italics">[see Dosage Forms and Strengths (<linkHtml href="#ID_2ab71eb5-7f1b-428e-bbe7-1afe9872ec23">3</linkHtml>)]</content>.</item>
                           <item>
                              <caption>•</caption>APRETUDE must be administered by a healthcare provider by gluteal intramuscular injection <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_debb9a3b-2f0e-4ddd-9073-822e600d3ae0">2.7</linkHtml>)]</content>.</item>
                           <item>
                              <caption>•</caption>APRETUDE may be initiated with oral cabotegravir prior to the intramuscular injections or the patient may proceed directly to injection of APRETUDE without an oral lead-in <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_e4568929-5251-4637-9e91-ddf7d4eb8285">2.4</linkHtml>)]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">
                     <id root="ace4a3ca-d26d-4673-a96c-0e44381cbaa8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 HIV-1 Screening for Individuals Receiving APRETUDE for HIV-1 Pre-Exposure Prophylaxis </title>
                     <text>
                        <paragraph>Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. If an antigen/antibody-specific test is used and provides negative results, then such negative results should be confirmed using an RNA-specific assay, even if the results of the RNA-assay are available after APRETUDE or oral cabotegravir administration <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bd42e99d-60aa-448e-b46f-7a843ce41b0a">
                     <id root="76b72fd2-9c0b-4064-a728-444d97e321c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Adherence to APRETUDE </title>
                     <text>
                        <paragraph>Prior to starting APRETUDE, healthcare providers should carefully select individuals who agree to the required injection dosing and testing schedule and counsel individuals about the importance of adherence to scheduled dosing visits to help reduce the risk of acquiring HIV-1 infection and development of resistance <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_1d87c661-c4a2-49ad-89fa-5eec92f51e27">2.1</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>, <linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>), Microbiology (<linkHtml href="#ID_46262e20-28f1-48a4-bee0-22d72cfcc877">12.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e4568929-5251-4637-9e91-ddf7d4eb8285">
                     <id root="0b46d89d-ceb5-4e36-8caa-40da5e71792d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE </title>
                     <text>
                        <paragraph>The healthcare provider and individual may decide to use an oral lead-in with oral cabotegravir prior to the initiation of APRETUDE to assess the tolerability of cabotegravir or the healthcare provider and individual may proceed directly to injection of APRETUDE without the use of an oral lead-in <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_e156ceb9-623e-4679-bb58-8914f683b2f9">2.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>No safety and efficacy data are available for use of APRETUDE without an oral lead-in <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>), Adverse Reactions (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>)].</content> However, in HIV-1 treatment clinical trials, data show that an oral lead-in is not needed to ensure adequate plasma cabotegravir exposure upon initiation of injections and that the safety and efficacy results of CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) were similar when administered with and without an oral lead-in.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e156ceb9-623e-4679-bb58-8914f683b2f9">
                     <id root="66a31f65-b137-42c7-ae60-1e607836e53e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Gluteal Intramuscular Injection Dosing with APRETUDE </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Initiation Injections</content>
                        </paragraph>
                        <paragraph>If an oral lead-in is used, initiation injections should be administered on the last day of oral lead‑in or within 3 days thereafter. The recommended initiation injection doses of APRETUDE in individuals is a single 600‑mg (3-mL) intramuscular injection of APRETUDE given 1 month apart for 2 consecutive months (<linkHtml href="#_RefTable_1">Table 1</linkHtml> and <linkHtml href="#_RefTable_2">Table 2</linkHtml>). Individuals may be given the second APRETUDE initiation injection up to 7 days before or after the date the individual is scheduled to receive the injections.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Continuation Injections</content>
                        </paragraph>
                        <paragraph>After the 2 initiation injection doses given consecutively 1 month apart, the recommended continuation injection dose of APRETUDE is a single 600-mg (3-mL) intramuscular injection of APRETUDE every 2 months (<linkHtml href="#_RefTable_2">Table 2</linkHtml>). Individuals may be given APRETUDE up to 7 days before or after the date the individual is scheduled to receive the injections.</paragraph>
                        <table ID="_RefTable_1" width="100%">
                           <caption>Table 1. Recommended Dosing Schedule (with Oral Lead-In) for Pre-Exposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg</caption>
                           <col width="36%"/>
                           <col width="32%"/>
                           <col width="32%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup> Should be administered on the last day of oral lead-in or within 3 days thereafter.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>b</sup> Individuals may be given APRETUDE up to 7 days before or after the date the individual is scheduled to receive the injections.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Oral Lead-In </content>
                                       <br/>
                                       <content styleCode="bold">(at Least 28 Days)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(Month Prior </content>
                                       <br/>
                                       <content styleCode="bold">to Starting Injections)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Intramuscular (Gluteal)</content>
                                       <br/>
                                       <content styleCode="bold">Initiation Injection </content>
                                       <br/>
                                       <content styleCode="bold">(Month 1 and Month 2)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Intramuscular (Gluteal) Continuation Injection </content>
                                       <br/>
                                       <content styleCode="bold">(Month 4 and </content>
                                       <br/>
                                       <content styleCode="bold">Every 2 Months Onwards)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Oral cabotegravir 30 mg by mouth once daily for 28 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>APRETUDE<sup>a</sup>
                                    </paragraph>
                                    <paragraph>600-mg (3 mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>APRETUDE<sup>b</sup>
                                    </paragraph>
                                    <paragraph>600-mg (3 mL)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_RefTable_2" cellpadding="0pt" width="100%">
                           <caption>Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-Exposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2" valign="top">
                                    <sup>a</sup> Individuals may be given APRETUDE up to 7 days before or after the date the individual is scheduled to receive the injections.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Intramuscular (Gluteal) </content>
                                       <br/>
                                       <content styleCode="bold">Initiation Injection </content>
                                       <br/>
                                       <content styleCode="bold">(Month 1 and Month 2)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Intramuscular (Gluteal) </content>
                                       <br/>
                                       <content styleCode="bold">Continuation Injection </content>
                                       <br/>
                                       <content styleCode="bold">(Month 4 and Every 2 Months Onwards)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>APRETUDE<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>APRETUDE<sup>a</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>600-mg (3 mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>600-mg (3 mL)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_56594e75-975d-48dc-a5bf-d9d368e9141e">
                     <id root="48ba2649-a9af-4deb-a4fb-b836e25a348f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Recommended Dosing Schedule for Missed Injections </title>
                     <text>
                        <paragraph>Adherence to the injection dosing schedule is strongly recommended <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_bd42e99d-60aa-448e-b46f-7a843ce41b0a">2.3</linkHtml>)]</content>. Individuals who miss a scheduled injection visit should be clinically reassessed to ensure resumption of APRETUDE remains appropriate <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>, <linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>)]</content>. Refer to <linkHtml href="#_RefTable_3">Table 3</linkHtml> for dosing recommendations after missed injections.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Planned Missed Injections</content>
                        </paragraph>
                        <paragraph>If an individual plans to miss a scheduled every-2-month continuation injection visit by more than 7 days, take daily oral cabotegravir for up to 2 months to replace 1 missed scheduled every-2-month injection. The recommended oral daily dose is one 30-mg tablet of oral cabotegravir. The first dose of oral cabotegravir (or alternative oral PrEP regimen) should be taken approximately 2 months after the last injection dose of APRETUDE. Restart injection with APRETUDE on the day oral cabotegravir dosing completes or within 3 days, thereafter, as recommended in <linkHtml href="#_RefTable_3">Table 3</linkHtml>. For oral PrEP durations greater than 2 months, an alternative regimen to oral cabotegravir is recommended.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Unplanned Missed Injections</content>
                        </paragraph>
                        <paragraph>If a scheduled injection visit is missed or delayed by more than 7 days and oral dosing has not been taken in the interim, clinically reassess the individual to determine if resumption of injection dosing remains appropriate <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>. If the injection dosing schedule will be continued, see <linkHtml href="#_RefTable_3">Table 3</linkHtml> for dosing recommendations.</paragraph>
                        <table ID="_RefTable_3" cellpadding="5.75pt" width="100%">
                           <caption>Table 3. Injection Dosing Recommendations after Missed Injections</caption>
                           <col width="38%"/>
                           <col width="62%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Time since Last Injection</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Recommendation</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">If second injection is missed and time since first injection is:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Less than or equal to 2 months</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Administer 600-mg (3-mL) gluteal intramuscular injection of APRETUDE as soon as possible, then continue to follow the every-2-month injection dosing schedule.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than 2 months</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Restart with 600-mg (3-mL) gluteal intramuscular injection of APRETUDE, followed by a second 600-mg (3-mL) initiation injection dose 1 month later. Then continue to follow the every-2-month injection dosing schedule thereafter.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">If third or subsequent injection is missed and time since prior injection is:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Less than or equal to 3 months</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Administer 600-mg (3-mL) intramuscular injection of APRETUDE as soon as possible, then continue with the every-2-month injection dosing schedule.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Greater than 3 months</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Restart with 600-mg (3-mL) gluteal intramuscular injection of APRETUDE, followed by the second 600-mg (3-mL) initiation injection dose 1 month later. Then continue with the every-2-month injection dosing schedule thereafter.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_debb9a3b-2f0e-4ddd-9073-822e600d3ae0">
                     <id root="1056a381-0ea9-4d2c-9350-04583fb8e71d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Administration Instructions</title>
                     <text>
                        <paragraph>Refer to the Instructions for Use for complete administration instructions with illustrations. Carefully follow these instructions and ensure that the vial adaptor is used correctly when preparing the suspension for injection to avoid leakage.</paragraph>
                        <paragraph>APRETUDE is a suspension for gluteal intramuscular injection that does not need further dilution or reconstitution.</paragraph>
                        <paragraph>The ventrogluteal site is recommended for injection. A dorsogluteal approach (upper outer quadrant) is acceptable, if preferred by the healthcare professional. Do not administer by any other route or anatomical site. Consider the body mass index (BMI) of the individual to ensure that the needle length is sufficient to reach the gluteus muscle. Longer needle lengths (not included in the dosing kit) may be required for individuals with higher BMI (e.g., &gt;30 kg/m<sup>2</sup>) to ensure that the injection is administered intramuscularly as opposed to subcutaneously.</paragraph>
                        <paragraph>If the pack has been stored in the refrigerator, the vial should be brought to room temperature prior to administration (not to exceed 30°C [86°F]). </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. The APRETUDE vial has a brown tint to the glass that may limit visual inspection. Discard the vial if the medicine exhibits particulate matter or discoloration.</paragraph>
                        <paragraph>Shake the vial vigorously so that the suspension looks uniform before injecting. Small air bubbles are expected and acceptable.</paragraph>
                        <paragraph>Once the suspension has been drawn into the syringe, the injection should be administered as soon as possible, but may remain in the syringe for up to 2 hours. The filled syringe should not be placed in the refrigerator. If the medicine remains in the syringe for more than 2 hours, the filled syringe and needle must be discarded <content styleCode="italics">[see How Supplied/Storage and Handling (<linkHtml href="#ID_69ae0649-5e98-4378-a58c-96ae69be2387">16</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2ab71eb5-7f1b-428e-bbe7-1afe9872ec23">
               <id root="3efe708d-d133-44aa-bea4-e014b08b9e1f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Injection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir extended‑release injectable suspension.</paragraph>
               </text>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: Single-dose vial of 600 mg/3 mL (200 mg/mL) of cabotegravir extended-release injectable suspension. (<linkHtml href="#ID_2ab71eb5-7f1b-428e-bbe7-1afe9872ec23">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">
               <id root="2ad48e45-d265-45d8-af10-ebbedf144e6e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>APRETUDE is contraindicated in individuals:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>with unknown or positive HIV-1 status <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>, <linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>with previous hypersensitivity reaction to cabotegravir <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)]</content>.</item>
                     <item>
                        <caption>•</caption>receiving the following coadministered drugs for which significant decreases in cabotegravir plasma concentrations may occur due to uridine diphosphate glucuronosyltransferase (UGT)1A1 enzyme induction, which may result in reduced effectiveness <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_15358dc8-7a1e-4506-90c1-ccc6f22d4c18">7.2</linkHtml>, <linkHtml href="#ID_a3f14517-a64d-435d-80e5-8f30f3cbdda2">7.3</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>:<list listType="unordered">
                           <item>
                              <caption>o</caption>Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin</item>
                           <item>
                              <caption>o</caption>Antimycobacterials: Rifampin, rifapentine</item>
                        </list>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Unknown or positive HIV-1 status. (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Previous hypersensitivity reaction to cabotegravir. (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Coadministration with drugs where significant decreases in cabotegravir plasma concentrations may occur. (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_9619b1b3-0506-45eb-bcd6-e75a4ee128bb">
               <id root="afada303-ef02-4ef9-a5bb-bbc1328f6dca"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Comprehensive management to reduce the risk of HIV-1 acquisition. (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Potential risk of developing resistance to APRETUDE if an individual acquires HIV-1 either before or while taking APRETUDE or following discontinuation of APRETUDE. Reassess risk of HIV-1 acquisition and test before each injection to confirm HIV-1 negative status. (<linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Residual concentrations of cabotegravir may remain in the systemic circulation of individuals up to 12 months or longer. (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Serious or severe hypersensitivity reactions have been reported with cabotegravir and include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Discontinue APRETUDE immediately if signs or symptoms of hypersensitivity reactions develop. (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hepatotoxicity has been reported in individuals receiving cabotegravir. Clinical and laboratory monitoring should be considered. Discontinue APRETUDE if hepatotoxicity is suspected. (<linkHtml href="#ID_7e73b8c5-7a44-467c-9f71-b4a17047f499">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Depressive disorders have been reported with APRETUDE. Prompt evaluation is recommended for depressive symptoms. (<linkHtml href="#ID_bff6684f-970f-4418-858a-2eeb57434723">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">
                     <id root="0e4ee773-daba-42c8-b3e5-b3dd1225c5f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection</title>
                     <text>
                        <paragraph>Use APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a comprehensive prevention strategy including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of sexually transmitted infections (STIs). APRETUDE is not always effective in preventing HIV-1 acquisition <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0b581734-cb2d-4edd-86ec-c3c2585021b9">14.1</linkHtml>)]</content>. The time from initiation of APRETUDE for HIV-1 PrEP to maximal protection against HIV-1 infection is unknown.</paragraph>
                        <paragraph>Risk for HIV-1 acquisition includes behavioral, biological, or epidemiologic factors including, but not limited to, condomless sex, past or current STIs, self-identified HIV risk, having sexual partners of unknown HIV-1 viremic status, or sexual activity in a high prevalence area or network.</paragraph>
                        <paragraph>Counsel individuals on the use of other prevention measures (e.g., consistent and correct condom use; knowledge of partner(s)’ HIV-1 status, including viral suppression status; regular testing for STIs that can facilitate HIV-1 transmission). Inform individuals about and support their efforts in reducing sexual risk behavior.</paragraph>
                        <paragraph>Use APRETUDE to reduce the risk of acquiring HIV-1 only in individuals confirmed to be HIV‑1 negative <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>)]</content>. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV‑1 infection who are taking only APRETUDE, because APRETUDE alone does not constitute a complete regimen for HIV-1 treatment <content styleCode="italics">[see Microbiology (<linkHtml href="#ID_46262e20-28f1-48a4-bee0-22d72cfcc877">12.4</linkHtml>)]</content>; therefore, care should be taken to minimize the risk of initiating or continuing APRETUDE before confirming the individual is HIV-1 negative.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Prior to initiating APRETUDE for HIV-1 PrEP, ask seronegative individuals about recent (in past month) potential exposure events (e.g., condomless sex or condom breaking during sex with a partner of unknown HIV-1 status or unknown viremic status, a recent STI), and evaluate for current or recent signs or symptoms consistent with acute HIV-1 infection (e.g., fever, fatigue, myalgia, skin rash).</item>
                           <item>
                              <caption>•</caption>If recent (&lt;1 month) exposures to HIV-1 are suspected or clinical symptoms consistent with acute HIV-1 infection are present, use a test approved or cleared by the FDA as an aid in the diagnosis of acute or primary HIV-1 infection.</item>
                        </list>
                        <paragraph>When using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each injection and upon diagnosis of any other STIs <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>, <linkHtml href="#ID_e156ceb9-623e-4679-bb58-8914f683b2f9">2.5</linkHtml>)]</content>. </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>If an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent with acute HIV-1 infection develop following an exposure event, additional HIV testing to determine HIV status is needed. If an individual has confirmed HIV-1 infection, then the individual must be transitioned to a complete HIV-1 treatment regimen. </item>
                        </list>
                        <paragraph>Counsel individuals without HIV-1 to strictly adhere to the recommended dosing and testing schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the potential development of resistance <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_bd42e99d-60aa-448e-b46f-7a843ce41b0a">2.3</linkHtml>, <linkHtml href="#ID_e156ceb9-623e-4679-bb58-8914f683b2f9">2.5</linkHtml>), Microbiology (<linkHtml href="#ID_46262e20-28f1-48a4-bee0-22d72cfcc877">12.4</linkHtml>)]</content>. Some individuals, such as adolescents, may benefit from frequent visits and counseling to support adherence to the dosing and testing schedule <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_70a09f07-3a84-4265-b7fa-fed80f3dbb3f">8.4</linkHtml>), Microbiology (<linkHtml href="#ID_46262e20-28f1-48a4-bee0-22d72cfcc877">12.4</linkHtml>), Clinical Studies (<linkHtml href="#ID_a2396e75-47f6-456b-af7b-bedec3752285">14</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">
                     <id root="8a791512-aaf7-4d29-890a-1bce73fd7173"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Potential Risk of Resistance with APRETUDE </title>
                     <text>
                        <paragraph>There is a potential risk of developing resistance to APRETUDE if an individual acquires HIV-1 either before or while taking APRETUDE or following discontinuation of APRETUDE <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>, <linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>To minimize this risk, it is essential to clinically reassess individuals for risk of HIV-1 acquisition and to test before each injection to confirm HIV-1 negative status. Individuals who are confirmed to have HIV-1 infection must transition to a complete HIV-1 treatment regimen.</paragraph>
                        <paragraph>Alternative forms of PrEP should be considered following discontinuation of APRETUDE for those individuals at continuing risk of HIV-1 acquisition and initiated within 2 months of the final injection of APRETUDE.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">
                     <id root="5c35df75-a56b-4a8e-90ea-27060a3d8204"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Long-Acting Properties and Potential Associated Risks with APRETUDE  </title>
                     <text>
                        <paragraph>Residual concentrations of cabotegravir may remain in the systemic circulation of individuals for prolonged periods (up to 12 months or longer). It is important to carefully select individuals who agree to the required every-2-month injection dosing schedule because non-adherence to every‑2-monthly injections or missed doses could lead to HIV-1 acquisition and development of resistance.</paragraph>
                        <paragraph>Healthcare providers should take the prolonged-release characteristics of cabotegravir into consideration when APRETUDE is prescribed <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_bd42e99d-60aa-448e-b46f-7a843ce41b0a">2.3</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>, <linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>), Drug Interactions (<linkHtml href="#ID_f0f03072-95f3-4ab5-8f65-110866ca0af3">7.1</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_61de2542-73e5-4ad7-b044-ad0d6c2927af">8.1</linkHtml>, <linkHtml href="#ID_6cd6cd2b-7b85-467d-9e17-d55be43208e4">8.2</linkHtml>), Overdosage (<linkHtml href="#ID_4f085f3c-8130-4aaf-88a4-894d88969e2e">10</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">
                     <id root="6575b14b-2e83-4f47-ae52-6bd237fe3526"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Serious or severe hypersensitivity reactions have been reported with cabotegravir and include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_78194970-21ba-48a7-ba5d-a52ee32d79e7">6.2</linkHtml>)]</content>. Administration of cabotegravir oral lead-in dosing was used in clinical studies to help identify participants who may be at risk of a hypersensitivity reaction. Remain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_e4568929-5251-4637-9e91-ddf7d4eb8285">2.4</linkHtml>), Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Adverse Reactions (<linkHtml href="#ID_98e393f8-fb38-46df-a1be-7672e5b1f3fe">6</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph>Discontinue APRETUDE immediately if signs or symptoms of hypersensitivity reactions develop (including, but not limited to, severe rash, or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, mucosal involvement [oral blisters or lesions], conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema, difficulty breathing). Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated. For information regarding the long-acting properties of APRETUDE <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7e73b8c5-7a44-467c-9f71-b4a17047f499">
                     <id root="de209e79-0586-4713-812e-9cb093605b13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hepatotoxicity </title>
                     <text>
                        <paragraph>Hepatotoxicity has been reported in a limited number of individuals receiving cabotegravir with or without known pre-existing hepatic disease or identifiable risk factors <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Clinical and laboratory monitoring should be considered and APRETUDE should be discontinued if hepatotoxicity is suspected and individuals managed as clinically indicated. For information regarding the long-acting properties of APRETUDE <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bff6684f-970f-4418-858a-2eeb57434723">
                     <id root="ca10782f-a0be-4595-8a0e-40d4ffefa17f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Depressive Disorders </title>
                     <text>
                        <paragraph>Depressive disorders (including depression, depressed mood, major depression, persistent depressive disorder, suicidal ideation, suicide attempt) have been reported with APRETUDE <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>)]</content>. Promptly evaluate individuals with depressive symptoms to assess whether the symptoms are related to APRETUDE and to determine whether the risks of continued therapy outweigh the benefits.</paragraph>
                     </text>
                     <effectiveTime value="20231213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1e95108b-bdb6-40da-bf50-d7a75ce69908">
                     <id root="053423bb-c1b1-42fe-9377-aa906f04a975"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions </title>
                     <text>
                        <paragraph>The concomitant use of APRETUDE and other drugs may result in reduced drug concentration of APRETUDE <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Drug Interactions (<linkHtml href="#ID_15358dc8-7a1e-4506-90c1-ccc6f22d4c18">7.2</linkHtml>, <linkHtml href="#ID_a3f14517-a64d-435d-80e5-8f30f3cbdda2">7.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>See <linkHtml href="#_RefTable_8">Table 8</linkHtml> for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during use of, and after discontinuation of APRETUDE; review concomitant medications during use of APRETUDE <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_a3f14517-a64d-435d-80e5-8f30f3cbdda2">7.3</linkHtml>, <linkHtml href="#ID_a195231a-5bc4-4ca0-a06a-4a03324c50c3">7.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_98e393f8-fb38-46df-a1be-7672e5b1f3fe">
               <id root="c4f3730e-e462-4df4-b7e9-1c98a6378e57"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following adverse reactions are described below and in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7e73b8c5-7a44-467c-9f71-b4a17047f499">5.5</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Depressive disorders <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_bff6684f-970f-4418-858a-2eeb57434723">5.6</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (all grades) observed in at least 1% of participants receiving APRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, and upper respiratory tract infection. (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_cc848be4-6289-4f39-b214-512da57251ee">
                     <id root="1ff97db8-4f17-474d-8621-f78f21af26fb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Trials Experience in Adults</content>
                        </paragraph>
                        <paragraph>The safety assessment of APRETUDE is based on the analysis of data from 2 international, multicenter, double-blind trials, HPTN 083 and HPTN 084 <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0b581734-cb2d-4edd-86ec-c3c2585021b9">14.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Adverse reactions were reported while on blinded study product following exposure to APRETUDE extended-release injectable suspension and oral cabotegravir tablets as oral lead-in. The median time on blinded study product in HPTN 083 was 65 weeks and 2 days (range: 1 day to 156 weeks and 1 day), with a total exposure on cabotegravir of 3,231 person‑years. The median time on blinded study product in HPTN 084 was 64 weeks and 1 day (range: 1 day to 153 weeks and 1 day), with a total exposure on cabotegravir of 2,009 person‑years.</paragraph>
                        <paragraph>The most common adverse reactions regardless of severity reported in at least 1% of participants in HPTN 083 or HPTN 084 are presented in <linkHtml href="#_RefTable_4">Table 4</linkHtml>.</paragraph>
                        <paragraph>In HPTN 083, 6% of participants in the group receiving APRETUDE intramuscular injection every 2 months and 4% of participants receiving oral TRUVADA [emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)] once daily discontinued due to adverse events (all causality). Non-injection-site–associated adverse events leading to discontinuation and occurring in ≥1% of participants were increased alanine aminotransferase with APRETUDE and TRUVADA.</paragraph>
                        <paragraph>In HPTN 084, 1% of participants receiving APRETUDE and 1% of participants receiving TRUVADA discontinued due to adverse events. The most commonly reported adverse event (all causality) leading to discontinuation was increased alanine aminotransferase (&lt;1%) with APRETUDE and TRUVADA. The side-by-side tabulation is to simplify presentation; direct comparison across trials should not be made due to differing trials.</paragraph>
                        <table ID="_RefTable_4" width="100%">
                           <caption>Table 4. Adverse Drug Reactions<sup>a</sup> (All Grades) Reported in at Least 1% of Participants Receiving APRETUDE in Either HPTN 083 or HPTN 084</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Adverse reactions defined as “treatment-related” as assessed by the investigator, with exception of injection site reactions, where all injection site reactions were reported regardless of causality.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>b</sup> Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA (n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>c</sup> Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>d</sup> Fatigue includes fatigue, malaise.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>e</sup> Sleep disorders includes insomnia, abnormal dreams.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>f</sup> Abdominal pain includes abdominal pain, upper abdominal pain.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>g</sup> Rash includes rash, erythema, pruritis, macular, papular, maculopapular.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 083</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 084</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Every 2 Months</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 2,281)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Once Daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 2,285)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Every 2 Months</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 1,614)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Once Daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 1,610)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Injection site reactions<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>82%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>35%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>38%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>11%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>13%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pyrexia<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Fatigue<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Sleep disorders<sup>e</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>8%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Flatulence</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abdominal pain<sup>f</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Myalgia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Rash<sup>g</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Decreased appetite</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Somnolence</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Back pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>Upper respiratory tract infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Injection-Associated Adverse Reactions: Local Injection Site Reactions (ISRs) with APRETUDE:</content> The most frequent adverse reactions associated with the intramuscular administration of APRETUDE in HPTN 083 were ISRs. After 20,286 injections, 8,900 ISRs were reported. Of the 2,117 participants who received at least one injection of APRETUDE, 1,740 (82%) participants experienced at least one ISR, of which a total of 3% of participants discontinued APRETUDE because of ISRs. Among the participants who received APRETUDE and experienced at least one ISR, the maximum severity of reactions was mild (Grade 1) in 41% of participants, moderate (Grade 2) in 56% of participants, and severe (Grade 3) in 3% of participants. The median duration of overall ISR events was 4 days. The proportion of participants reporting ISRs at each visit and the severity of the ISRs decreased over time. The most commonly reported ISRs (all causality and grades) in at least 1% of participants who received APRETUDE and experienced at least one ISR from HPTN 083 are presented in <linkHtml href="#_RefTable_5">Table 5</linkHtml>.</paragraph>
                        <paragraph>The most frequent adverse reactions associated with the intramuscular administration of APRETUDE in HPTN 084 were ISRs. After 13,068 injections, 1,171 ISRs were reported. Of the 1,519 participants who received at least one injection of APRETUDE, 578 (38%) participants experienced at least one ISR. No participants discontinued APRETUDE because of ISRs. Among the participants who received APRETUDE and experienced at least one ISR, the maximum severity of reactions was mild (Grade 1) in 66% of participants, moderate (Grade 2) in 34% of participants, and severe (Grade 3) in less than 1% of participants. The median duration of overall ISR events was 8 days. The proportion of participants reporting ISRs at each visit and the severity of the ISRs generally decreased over time. The most commonly reported ISRs (all causality and grades) in at least 1% of participants who received APRETUDE and experienced at least one ISR from HPTN 084 are presented in <linkHtml href="#_RefTable_5">Table 5</linkHtml>.</paragraph>
                        <table ID="_RefTable_5" width="100%">
                           <caption>Table 5. Injection Site Reactions (All Grades) Reported in at Least 1% of Participants Who Experienced at Least One Injection Site Reaction (All Causality) with APRETUDE in Either HPTN 083 or HPTN 084</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Placebo injectable suspension: intralipid 20% fat emulsion.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Injection Site Reactions</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 083</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 084</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 1,740)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 724)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 578)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 166)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pain/tenderness</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>98%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>95%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>90%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>87%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nodules</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>15%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>14%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Induration</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>15%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Swelling</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>18%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Bruising </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Erythema</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>11%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Warmth</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anesthesia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abscess</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Discoloration</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">          Other Injection-Associated Adverse Reactions: </content>In the HPTN 083 clinical trial, an increased incidence of pyrexia (including pyrexia, feeling hot, chills, influenza-like illness) (4%) was reported by participants receiving APRETUDE compared with participants receiving TRUVADA (&lt;1%). There were no differences reported in the incidence of pyrexia between groups in HPTN 084.</paragraph>
                        <paragraph>Vasovagal or pre-syncopal reactions considered treatment related were reported in &lt;1% of participants after injection with APRETUDE in HPTN 083. None were reported as treatment related by the investigators in HPTN 084.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Less Common Adverse Reactions:</content> The following select adverse reactions (regardless of severity) occurred in &lt;1% of participants receiving APRETUDE in HPTN 083 or HPTN 084.</paragraph>
                        <paragraph>
                           <content styleCode="italics">          Hepatobiliary Disorders:</content> Hepatotoxicity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">          Investigations: </content>Weight increase (see below).</paragraph>
                        <paragraph>
                           <content styleCode="italics">          Psychiatric Disorders: Depression; suicidal ideation, and suicide attempt (these events were observed primarily in participants with a pre‑existing history of depression or other psychiatric illness).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Weight Increase: </content>At the Week 41 and Week 97 timepoints in HPTN 083, participants who received APRETUDE gained a median of 1.2 kg (Interquartile Range [IQR]; -1.0, 3.5; n = 1,623) and 2.1 kg (IQR; -0.9, 5.9; n = 601) in weight from baseline. Those who received TRUVADA gained a median of 0 kg (IQR; -2.1, 2.4; n = 1,611) and 1 kg (IQR; -1.9, 4.0; n = 598) in weight from baseline, respectively.</paragraph>
                        <paragraph>At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE gained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in weight from baseline, respectively. Those who received TRUVADA gained a median of 1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from baseline, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Laboratory Abnormalities: </content>Grade 3 or 4 post-baseline maximum toxicity laboratory abnormalities for HPTN 083 or HPTN 084 are summarized in <linkHtml href="#_RefTable_6">Table 6</linkHtml>.</paragraph>
                        <table ID="_RefTable_6" width="100%">
                           <caption>Table 6. Laboratory Abnormalities (Grades 3 to 4) in ≥1% of Participants in Either HPTN 083 or HPTN 084</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">ALT = Alanine transaminase, ULN = upper limit of normal, AST = Aspartate aminotransferase.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Laboratory Parameter</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 083</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 084</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Every 2 Months</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 2,281)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Once Daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 2,285)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Every 2 Months</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 1,614)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Once Daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n = 1,610)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ALT (≥5.0 x ULN)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>AST (≥5.0 x ULN)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Creatine phosphokinase (≥10.0 x ULN)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>15%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>14%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Lipase (≥3.0 x ULN)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Creatinine (&gt;1.8 x ULN) or increase to ≥1.5 x baseline)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>5%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">          Serum Lipids: </content>Changes from baseline to Month 15 in total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and total cholesterol to HDL ratio in HPTN 083 and HPTN 084 are presented in <linkHtml href="#_RefTable_7">Table 7</linkHtml>.</paragraph>
                        <table ID="_RefTable_7" width="100%">
                           <caption>Table 7. Fasting Lipid Values, Median Change from Baseline<sup>a</sup> at Week 57, Reported in HPTN 083 and HPTN 084</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Nearly 60% of participants with baseline data available had Week 57 data available in both arms of both trials. Within each trial, baseline values were comparable among participants receiving APRETUDE and TRUVADA.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom"/>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 083</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">HPTN 084</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Total cholesterol (mg/dL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>+1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-10.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>+0.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-3.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>LDL cholesterol (mg/dL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>+1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-6.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-1.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-5.0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>HDL cholesterol (mg/dL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-0.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-3.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>-2.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Triglycerides (mg/dL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>+2.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>+3.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>+0.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Total cholesterol:<br/>HDL cholesterol ratio</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>+0.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>+0.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>+0.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>+0.1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Clinical Trials Experience in Adolescents</content>
                        </paragraph>
                        <paragraph>In adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to the safety data reported in adults receiving APRETUDE for HIV-1 PrEP <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_70a09f07-3a84-4265-b7fa-fed80f3dbb3f">8.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_78194970-21ba-48a7-ba5d-a52ee32d79e7">
                     <id root="cba13410-d826-4d0f-ba82-935493de79bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postmarketing use of APRETUDE or cabotegravir-containing regimens. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune System Disorders</content>
                        </paragraph>
                        <paragraph>Hypersensitivity reactions (including angioedema and urticaria) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Skin and Subcutaneous Tissue Disorders</content>
                        </paragraph>
                        <paragraph>Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2759f01b-6e1e-457a-b703-ffceb8a88a43">
               <id root="d2f44193-8c6d-4c8f-83d8-0ad9d2f0a017"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Refer to the full prescribing information for important drug interactions with APRETUDE. (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>, <linkHtml href="#ID_1e95108b-bdb6-40da-bf50-d7a75ce69908">5.7</linkHtml>, <linkHtml href="#ID_2759f01b-6e1e-457a-b703-ffceb8a88a43">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Drugs that induce uridine diphosphate glucuronosyltransferase (UGT)1A1 may significantly decrease plasma concentrations of cabotegravir. (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>, <linkHtml href="#ID_15358dc8-7a1e-4506-90c1-ccc6f22d4c18">7.2</linkHtml>, <linkHtml href="#ID_a3f14517-a64d-435d-80e5-8f30f3cbdda2">7.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f0f03072-95f3-4ab5-8f65-110866ca0af3">
                     <id root="6fd4218c-45e2-4d0b-b6de-a8e306704b26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE</title>
                     <text>
                        <paragraph>Residual concentrations of cabotegravir may remain in the systemic circulation of individuals for prolonged periods (up to 12 months or longer). These residual concentrations are not expected to affect the exposures of antiretroviral drugs that are initiated after discontinuation of APRETUDE<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>), Drug Interactions (<linkHtml href="#ID_a195231a-5bc4-4ca0-a06a-4a03324c50c3">7.4</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_15358dc8-7a1e-4506-90c1-ccc6f22d4c18">
                     <id root="1a29338b-4096-433a-8a61-0f354a63bef3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Potential for Other Drugs to Affect APRETUDE </title>
                     <text>
                        <paragraph>Cabotegravir is primarily metabolized by UGT1A1 with some contribution from UGT1A9. Drugs that are strong inducers of UGT1A1 or 1A9 are expected to decrease cabotegravir plasma concentrations; therefore, coadministration of APRETUDE with these drugs is contraindicated <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a3f14517-a64d-435d-80e5-8f30f3cbdda2">
                     <id root="d60858fd-f783-4643-8fa3-af900cbc4266"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Established and Other Potentially Significant Drug Interactions </title>
                     <text>
                        <paragraph>Information regarding potential drug interactions with cabotegravir is provided in <linkHtml href="#_RefTable_8">Table 8</linkHtml>. These recommendations are based on either drug interaction trials following oral administration of cabotegravir or predicted interactions due to the expected magnitude of the interaction <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_1e95108b-bdb6-40da-bf50-d7a75ce69908">5.7</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>. <linkHtml href="#_RefTable_8">Table 8</linkHtml> includes potentially significant interactions but is not all inclusive.</paragraph>
                        <table ID="_RefTable_8" width="100%">
                           <caption>Table 8. Drug Interactions with APRETUDE</caption>
                           <col width="30%"/>
                           <col width="22%"/>
                           <col width="48%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">↑ = Increase, ↓ = Decrease, ↔ = No change.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Concomitant Drug Class: </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Drug Name</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Effect on Concentration</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Clinical Comment</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anticonvulsants:</paragraph>
                                    <paragraph>Carbamazepine</paragraph>
                                    <paragraph>Oxcarbazepine</paragraph>
                                    <paragraph>Phenobarbital</paragraph>
                                    <paragraph>Phenytoin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>↓Cabotegravir</paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Coadministration is contraindicated with APRETUDE due to potential for significant decreases in plasma concentration of APRETUDE.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antimycobacterials:</paragraph>
                                    <paragraph>Rifampin</paragraph>
                                    <paragraph>Rifapentine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>↓Cabotegravir</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Antimycobacterial:</paragraph>
                                    <paragraph>Rifabutin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>↓Cabotegravir</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>When rifabutin is started before or concomitantly with the first initiation injection of APRETUDE, the recommended dosing of APRETUDE is one 600-mg (3-mL) injection, followed 2 weeks later by a second 600‑mg (3-mL) initiation injection and monthly thereafter while on rifabutin. When rifabutin is started at the time of the second initiation injection or later, the recommended dosing schedule of APRETUDE is 600‑mg (3 mL) monthly while on rifabutin.</paragraph>
                                    <paragraph>After stopping rifabutin, the recommended dosing schedule of APRETUDE is 600-mg (3 mL) every 2 months.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a195231a-5bc4-4ca0-a06a-4a03324c50c3">
                     <id root="dfbe8163-79f1-4d04-80d0-fa9abc3ca2c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs without Clinically Significant Interactions with Cabotegravir </title>
                     <text>
                        <paragraph>Based on drug interaction study results, the following drugs can be coadministered with cabotegravir (non-antiretrovirals) or given after discontinuation of cabotegravir (antiretrovirals and non-antiretrovirals) without a dose adjustment: etravirine, midazolam, oral contraceptives containing levonorgestrel and ethinyl estradiol, and rilpivirine <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e831e2ad-2bbd-4e2f-8db1-9e9cd750be15">
               <id root="60a584db-3362-4b7c-920b-4a53417191ac"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20240920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Lactation: Assess the benefit-risk of using APRETUDE to the infant while breastfeeding due to the potential for adverse reactions and residual concentrations in the systemic circulation for up to 12 months or longer after discontinuation. (<linkHtml href="#ID_6cd6cd2b-7b85-467d-9e17-d55be43208e4">8.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pediatrics: Not recommended in individuals weighing &lt;35 kg. (<linkHtml href="#ID_70a09f07-3a84-4265-b7fa-fed80f3dbb3f">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_61de2542-73e5-4ad7-b044-ad0d6c2927af">
                     <id root="2de91215-85b5-4f2a-8a46-48991ff8e469"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to APRETUDE during pregnancy. Healthcare providers are encouraged to register individuals by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are insufficient human data on the use of APRETUDE during pregnancy to adequately assess a drug-associated risk of birth defects and miscarriage. Discuss the benefit-risk of using APRETUDE with individuals of childbearing potential or during pregnancy.</paragraph>
                        <paragraph>Cabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.</paragraph>
                        <paragraph>The APR has been established to monitor for birth defects following prenatal exposure to antiretrovirals. The rate of miscarriage is not reported in the APR. The background rate for major birth defects in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) is 2.7%. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%. The APR uses the MACDP as the U.S. reference population for birth defects in the general population. The MACDP evaluates mothers and infants from a limited geographic area and does not include outcomes for births that occurred at &lt;20 weeks’ gestation.</paragraph>
                        <paragraph>In animal reproduction studies with oral cabotegravir, a delay in the onset of parturition and increased stillbirths and neonatal deaths were observed in a rat pre- and postnatal development study at &gt;28 times the exposure at the recommended human dose (RHD). No evidence of adverse developmental outcomes was observed with oral cabotegravir in rats or rabbits (&gt;28 times or similar to the exposure at the RHD, respectively) given during organogenesis <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Cabotegravir is detected in systemic circulation for up to 12 months or longer after discontinuing injections of APRETUDE; therefore, consideration should be given to the potential for fetal exposure during pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data:</content> Cabotegravir was administered orally to pregnant rats at 0, 0.5, 5, or 1,000 mg/kg/day from 15 days before cohabitation, during cohabitation, and from Gestation Days 0 to 17. There were no effects on fetal viability when fetuses were delivered by caesarean, although a minor decrease in fetal body weight was observed at 1,000 mg/kg/day (&gt;28 times the exposure in humans at the RHD). No drug-related fetal toxicities were observed at 5 mg/kg/day (approximately 13 times the exposure in humans at the RHD), and no drug-related fetal malformations were observed at any dose.</paragraph>
                        <paragraph>Cabotegravir was administered orally to pregnant rabbits at 0, 30, 500, or 2,000 mg/kg/day from Gestation Days 7 to 19. No drug-related fetal toxicities were observed at 2,000 mg/kg/day (approximately 0.7 times the exposure in humans at the RHD).</paragraph>
                        <paragraph>In a rat pre- and postnatal development study, cabotegravir was administered orally to pregnant rats at 0, 0.5, 5, or 1,000 mg/kg/day from Gestation Day 6 to Lactation Day 21. A delay in the onset of parturition and increases in the number of stillbirths and neonatal deaths by Lactation Day 4 were observed at 1,000 mg/kg/day (&gt;28 times the exposure in humans at the RHD); there were no alterations to growth and development of surviving offspring. In a cross-fostering study, similar incidences of stillbirths and early postnatal deaths were observed when rat pups born to cabotegravir-treated mothers were nursed from birth by control mothers. There was no effect on neonatal survival of control pups nursed from birth by cabotegravir-treated mothers. A lower dose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with delayed parturition or neonatal mortality in rats. Studies in pregnant rats showed that cabotegravir crosses the placenta and can be detected in fetal tissue.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6cd6cd2b-7b85-467d-9e17-d55be43208e4">
                     <id root="6e4a63ef-9e30-4e1c-81d2-833306a4a6d3"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of cabotegravir in human milk. Cabotegravir is present in animal milk <content styleCode="italics">(see Data)</content>. When a drug is present in animal milk, it is likely that the drug will be present in human milk. It is not known if cabotegravir affects human milk production, or has effects on the breastfed infant. If cabotegravir is present in human milk, residual exposures may remain for 12 months or longer after the last injections have been administered <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Cabotegravir concentrations may be detectable in systemic circulation for up to 12 months or longer after discontinuing injections of APRETUDE. Breastfeeding should only be considered if the expected benefit justifies the potential risk to the infant, including the potential risk for adverse reaction in the breastfed child, along with the risk of HIV-1 acquisition due to nonadherence and subsequent vertical transmission to the child. Breastfeeding is not recommended if acute HIV-1 infection is suspected to avoid the risk of postnatal transmission of HIV-1 infection.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>Animal lactation studies with cabotegravir have not been conducted. However, cabotegravir was detected in the plasma of nursing pups on Lactation Day 10 in the rat pre- and postnatal development study.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_70a09f07-3a84-4265-b7fa-fed80f3dbb3f">
                     <id root="e1c2df8d-419f-4254-bc61-a7cb5a745563"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of APRETUDE for HIV-1 PrEP in adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition is supported by data from 2 adequate and well-controlled trials of APRETUDE for HIV-1 PrEP in adults with additional safety and pharmacokinetic data from studies in adults with HIV-1 who were administered CABENUVA, and in adolescent participants with HIV-1 who were administered separate components of CABENUVA in addition to their current antiretroviral therapy <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_e156ceb9-623e-4679-bb58-8914f683b2f9">2.5</linkHtml>), Adverse Reactions (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>), Clinical Studies (<linkHtml href="#ID_0b581734-cb2d-4edd-86ec-c3c2585021b9">14.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>APRETUDE for HIV-1 PrEP was evaluated in 2 open-label multicenter clinical trials, HPTN 083-01 and HPTN 084-01, in adolescent individuals 12 to less than 18 years of age weighing at least 35 kg who are at risk for HIV-1 acquisition. Sixty-four adolescents were enrolled. Of these, 62 adolescent participants received one or more injections. In adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to the safety data reported in adults receiving APRETUDE for HIV-1 PrEP.</paragraph>
                        <paragraph>While using APRETUDE, HIV-1 testing should be conducted prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) and prior to each injection of APRETUDE. Adolescents may benefit from more frequent visits and counseling to support adherence to the dosing and testing schedule <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_0f57eaeb-64ed-4d5f-bba6-465074c060bc">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>The safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants younger than 12 years of age or weighing &lt;35 kg have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_423fb022-89ec-4549-832b-73db83fa3b97">
                     <id root="ff69efcb-572d-4c8c-a408-2daff63ed3a0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>No dose adjustment is required in elderly individuals. There are limited data available on the use of APRETUDE in individuals aged 65 years and older. In general, caution should be exercised in administration of APRETUDE in elderly individuals, reflecting greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5115c89a-90c7-43bf-ada1-5c2bbf56b47f">
                     <id root="ef5cf8cb-d860-4af9-a8d0-ae899c1c4aa8"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>Based on studies with oral cabotegravir, no dosage adjustment of APRETUDE is necessary for individuals with mild (creatinine clearance ≥60 to &lt;90 mL/min), moderate (creatinine clearance ≥30 to &lt;60 mL/min) or severe renal impairment (creatinine clearance ≥15 to &lt;30 mL/min) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>. In individuals with end-stage renal disease not on dialysis, effects on the pharmacokinetics of cabotegravir are unknown. As cabotegravir is &gt;99% protein bound, dialysis is not expected to alter exposures of cabotegravir.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5026ac6e-9a90-46ef-93d0-3c72ea524db8">
                     <id root="8a10028a-89e8-48bf-aa4a-d69e48f9705b"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment </title>
                     <text>
                        <paragraph>Based on studies with oral cabotegravir, no dosage adjustment of APRETUDE is necessary for individuals with mild or moderate hepatic impairment (Child-Pugh A or B). The effect of severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of cabotegravir is unknown <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_cd046f54-77f4-4aa4-8a40-1819f736837b">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4f085f3c-8130-4aaf-88a4-894d88969e2e">
               <id root="998f1566-6bdf-4fce-9a29-9d0c0a88c413"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>There is no known specific treatment for overdose with APRETUDE. If overdose occurs, monitor the individual and apply standard supportive treatment as required as well as observation of the clinical status of the individual. As APRETUDE is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis. Consider the prolonged exposure to APRETUDE following an injection when assessing treatment needs and recovery <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7e73b8c5-7a44-467c-9f71-b4a17047f499">5.5</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20230227"/>
            </section>
         </component>
         <component>
            <section ID="ID_ca87aaeb-5ed8-471d-b099-a9dccf73e097">
               <id root="1f7df5cf-19dc-49c0-81dc-daa29ebae525"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>APRETUDE contains cabotegravir extended-release injectable suspension, an HIV INSTI.</paragraph>
                  <paragraph>The chemical name of cabotegravir is (<content styleCode="italics">3S,11aR</content>)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide. The empirical formula is C<sub>19</sub>H<sub>17</sub>F<sub>2</sub>N<sub>3</sub>O<sub>5</sub> and the molecular weight is 405.35 g/mol. It has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id-1473592955" referencedObject="ID_5896b85c-b7cf-459c-b5a8-36df0d334584"/>
                  <paragraph>Cabotegravir extended-release injectable suspension is a white to light pink free-flowing suspension for intramuscular injection in a sterile single-dose vial. Each vial contains 3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol (35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL), and Water for Injection.</paragraph>
                  <paragraph>The vial stoppers are not made with natural rubber latex.</paragraph>
               </text>
               <effectiveTime value="20240920"/>
               <component>
                  <observationMedia ID="ID_5896b85c-b7cf-459c-b5a8-36df0d334584">
                     <text>Cabotegravir chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a7135d1b-3325-4e87-886a-2ad89014c0a4">
               <id root="2cf4058e-a7fb-47e0-99b5-b464d466286c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20240920"/>
               <component>
                  <section ID="ID_9fd92cfe-4681-42dd-8b73-a7f1004002a6">
                     <id root="2a517f8a-1a81-4fd2-b16d-b84b29d2c18e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Cabotegravir is an HIV-1 antiretroviral drug <content styleCode="italics">[see Microbiology (<linkHtml href="#ID_46262e20-28f1-48a4-bee0-22d72cfcc877">12.4</linkHtml>)]</content> in a long-acting formulation.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cedae99e-0021-4702-81c9-64b10bdc6a22">
                     <id root="953edf8c-ca5c-4f07-acc9-a7126368611e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a dose of cabotegravir 150 mg orally every 12 hours (10 times the recommended total daily oral lead‑in dosage of APRETUDE), the QT interval is not prolonged to any clinically relevant extent. Administration of 3 doses of cabotegravir 150 mg orally every 12 hours resulted in a geometric mean C<sub>max</sub> approximately 2.8- and 5.6-fold above the geometric mean steady-state C<sub>max</sub> associated with the recommended 30-mg dose of oral cabotegravir and the recommended 600-mg dose given every 2 months of cabotegravir extended-release injectable suspension, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cd046f54-77f4-4aa4-8a40-1819f736837b">
                     <id root="db562f16-3147-4a74-9714-d22c9f20b247"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption, Distribution, and Elimination</content>
                        </paragraph>
                        <paragraph>The pharmacokinetic properties of cabotegravir are provided in <linkHtml href="#_RefTable_9">Table 9</linkHtml>. The multiple-dose pharmacokinetic parameters are provided in <linkHtml href="#_RefTable_10">Table 10</linkHtml>. For the pharmacokinetic properties of oral cabotegravir, refer to the full prescribing information for VOCABRIA (cabotegravir).</paragraph>
                        <table ID="_RefTable_9" width="100%">
                           <caption>Table 9. Pharmacokinetic Properties of Cabotegravir</caption>
                           <col width="65%"/>
                           <col width="35%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2" valign="top">CSF = Cerebrospinal fluid.<br/>
                                    <sup>a</sup> When taken orally with a high-fat meal versus fasted, the AUC<sub>(0-inf)</sub> (geometric mean ratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).<br/>
                                    <sup>b</sup> The clinical relevance of CSF-to-plasma concentration ratios is unknown. Concentrations were measured at steady-state 1 week after intramuscular administration of cabotegravir extended-release injectable suspensions given monthly or every 2 months.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="2" valign="top">
                                    <sup>c</sup> Elimination half-life driven by slow absorption rate from the intramuscular injection site.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="2" valign="top">
                                    <sup>d</sup> Dosing in mass balance studies: single-dose oral administration of [<sup>14</sup>C] cabotegravir.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Absorption<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>T<sub>max</sub> (days), median</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Distribution</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>% Bound to human plasma proteins</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>&gt;99.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Blood-to-plasma ratio</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.52</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>CSF-to-plasma concentration ratio (median [range])<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.003</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.002 to 0.004)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Elimination</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>t<sub>1/2</sub> (weeks), mean<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5.6 to 11.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>    Metabolic pathways</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>UGT1A1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>UGT1A9 (minor)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    Major route of elimination</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Metabolism</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    % of dose excreted as total <sup>14</sup>C (unchanged drug) in urine<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>27 (0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    % of dose excreted as total <sup>14</sup>C (unchanged drug) in feces<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>59 (47)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_RefTable_10" width="100%">
                           <caption>Table 10. Pharmacokinetic Parameters following Once-Daily Oral Cabotegravir and following Initiation and Every-2-Month Continuation Intramuscular Injections of APRETUDE</caption>
                           <col width="29%"/>
                           <col width="20%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">IM = Intramuscular.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>a</sup> Pharmacokinetic parameter values were based on individual post-hoc estimates from cabotegravir population pharmacokinetic models for patients in Phase 3 treatment studies of HIV treatment.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>b</sup> tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection, and 2 months for every 2 months for intramuscular injections of extended-release injectable suspension.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>c</sup> Oral lead-in pharmacokinetic parameter values represent steady state.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>d</sup> Initial injection C<sub>max</sub> values primarily reflect oral dosing because the initial injection was administered on the same day as the last oral dose; however, AUC<sub>(0-tau)</sub> and the C<sub>tau</sub> values reflect the initial injection. When administered without oral lead-in to recipients with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile) C<sub>max</sub> (1-week post‑initial injection) was 1.89 mcg/mL (0.438, 5.69) and C<sub>tau</sub> was 1.43 mcg/mL (0.403, 3.90).</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="5" valign="top">
                                    <sup>e</sup> Pharmacokinetic parameter values represent steady state.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dosing Phase</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dosage Regimen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Geometric Mean (5<sup>th</sup>, 95<sup>th</sup> Percentile)<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>(0-tau)</sub>
                                          <sup>b</sup>
                                       </content>
                                       <br/>
                                       <content styleCode="bold">(mcg•h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                       <br/>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>tau</sub>
                                          <sup>b</sup>
                                       </content>
                                       <br/>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Oral lead-in<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>145</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>8.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>4.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(93.5, 224)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(5.3, 11.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(2.8, 7.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Initial injection<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>600 mg IM</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,591</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>8.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>initial dose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(714; 3,245)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(5.3, 11.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.65, 2.9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Every-2-month injection<sup>e</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>600 mg IM</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>3,764</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>4.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>every 2 months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(2,431; 5,857)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(2.3, 6.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.8, 3.0)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of cabotegravir were observed based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are no data available for the use of cabotegravir in participants with hepatitis B virus and hepatitis C virus co-infection in PrEP studies.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment:</content> With oral cabotegravir, no clinically significant differences in the pharmacokinetics of cabotegravir are expected in individuals with mild, moderate, or severe renal impairment. Cabotegravir has not been studied in participants with end-stage renal disease not on dialysis. As cabotegravir is &gt;99% protein bound, dialysis is not expected to alter exposures of cabotegravir <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_5115c89a-90c7-43bf-ada1-5c2bbf56b47f">8.6</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment:</content> No clinically significant differences in the pharmacokinetics of cabotegravir are expected in mild to moderate (Child-Pugh A or B) hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of cabotegravir has not been studied <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_5026ac6e-9a90-46ef-93d0-3c72ea524db8">8.7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender: </content>Population pharmacokinetic analyses revealed no clinically relevant effect of gender on the exposure of cabotegravir. In addition, no clinically relevant differences in plasma cabotegravir concentrations were observed in PrEP studies by gender, including in cisgender men and transgender women (+/- hormone use). Therefore, no dose adjustment is necessary based on gender. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatrics:</content> No dose adjustment is required in elderly individuals. There are limited data available on the use of cabotegravir in individuals aged 65 years and older. In general, caution should be exercised in administration of cabotegravir in elderly individuals, reflecting greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_423fb022-89ec-4549-832b-73db83fa3b97">8.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatrics:</content> Population pharmacokinetic analyses revealed no clinically relevant differences in exposure between adolescent participants and adult participants with and without HIV-1 from the cabotegravir development program; therefore, no dosage adjustment is needed for adolescents weighing ≥35 kg (<linkHtml href="#_RefTable_11">Table 11</linkHtml>). </paragraph>
                        <table ID="_RefTable_11" width="100%">
                           <caption>Table 11. Pharmacokinetic Parameters following Once-Daily Oral Cabotegravir and following Initiation and Every-2-Month Continuation Intramuscular Injections of APRETUDE in Adolescent Participants Aged 12 to Younger than 18 Years (≥35 kg)</caption>
                           <col width="22%"/>
                           <col width="17%"/>
                           <col width="22%"/>
                           <col width="17%"/>
                           <col width="22%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5" valign="top">IM = intramuscular.<br/>
                                    <sup>a</sup> Pharmacokinetic parameter values were based on individual post-hoc estimates from population pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing 35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. <br/>
                                    <sup>b</sup> tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection, and 2 months for every 2 months for intramuscular injections of extended-release injectable suspension.<br/>
                                    <sup>c</sup> Oral lead-in pharmacokinetic parameter values represent steady state.<br/>
                                    <sup>d</sup> Initial injection C<sub>max</sub> values primarily reflect oral dosing because the initial injection was administered on the same day as the last oral dose; however, the AUC<sub>(0-tau)</sub> and C<sub>tau</sub> values reflect the initial injection.<br/>
                                    <sup>e</sup> Pharmacokinetic parameter values represent steady state.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dosing Phase</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dosage Regimen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Geometric Mean (5<sup>th</sup>, 95<sup>th</sup> Percentile)<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">AUC<sub>(0-tau)</sub>
                                          <sup>b</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg•h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>tau</sub>
                                          <sup>b</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Oral lead-in<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>203</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>10.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>6.43</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(136, 320)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(7.36, 16.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(4.15, 10.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Initial injection<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>600 mg IM</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2,085</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>10.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.88</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>initial dose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(1,056; 4,259)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(7.42, 16.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.801, 3.71)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Every-2-month injection<sup>e</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>600 mg IM</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>5,184</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>5.10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.54</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>every 2 months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(3,511; 7,677)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(3.06, 8.24)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(1.25, 4.19)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Cabotegravir is not a clinically relevant inhibitor of the following enzymes and transporters: cytochrome P450 (CYP)1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4; UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B15, and 2B17; P-glycoprotein (P‑gp); breast cancer resistance protein (BCRP); bile salt export pump (BSEP); organic cation transporter (OCT)1, OCT2; organic anion transporter polypeptide (OATP)1B1, OATP1B3; multidrug and toxin extrusion transporter (MATE) 1, MATE 2-K; and multidrug resistance protein (MRP)2 or MRP4.</paragraph>
                        <paragraph>In vitro, cabotegravir inhibited renal OAT1 (IC<sub>50</sub> = 0.81 microM) and OAT3 (IC<sub>50</sub> = 0.41 microM). Based on physiologically based pharmacokinetic (PBPK) modeling, cabotegravir may increase the AUC of OAT1/3 substrates up to approximately 80%.</paragraph>
                        <paragraph>In vitro, cabotegravir did not induce CYP1A2, CYP2B6, or CYP3A4.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">‎</content>
                           </content>Simulations using PBPK modeling show that no clinically significant interaction is expected during coadministration of cabotegravir with drugs that inhibit UGT1A1.</paragraph>
                        <paragraph>In vitro, cabotegravir was not a substrate of OATP1B1, OATP1B3, OATP2B1, or OCT1.</paragraph>
                        <paragraph>Cabotegravir is a substrate of P-gp and BCRP in vitro; however, because of its high permeability, no alteration in cabotegravir absorption is expected with coadministration of P-gp or BCRP inhibitors.</paragraph>
                        <paragraph>Drug interaction studies were not conducted with injectable cabotegravir. Drug interaction studies with oral cabotegravir are summarized in Tables <linkHtml href="#_RefTable_12">12</linkHtml> and <linkHtml href="#_RefTable_13">13</linkHtml>.</paragraph>
                        <table ID="_RefTable_12" cellpadding="5.75pt" width="100%">
                           <caption>Table 12. Effect of Coadministered Drugs on the Pharmacokinetics of Cabotegravir</caption>
                           <col width="20%"/>
                           <col width="15%"/>
                           <col width="5%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6" valign="top">n = Maximum number of participants with data, CI = Confidence Interval.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Coadministered Drug(s)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">and Dose(s)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of Cabotegravir</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Geometric Mean Ratio (90% CI) of Cabotegravir Pharmacokinetic Parameters with/without Coadministered Drugs</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">No Effect = 1.00</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">AUC</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>tau</sub> or C<sub>24</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Etravirine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.04</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.01</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.00</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    200 mg twice daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.99, 1.09)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.96, 1.06)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.94, 1.06)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Rifabutin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.83</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.77</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.74</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    300 mg once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.76, 0.90)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.74, 0.83)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.70, 0.78)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Rifampin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30-mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.94</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.41</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.50</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    600 mg once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>single dose</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.87, 1.02)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.36, 0.46)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.44, 0.57)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Rilpivirine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.05</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    25 mg once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.96, 1.15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(1.05, 1.19)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(1.04, 1.24)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_RefTable_13" cellpadding="5.75pt" width="100%">
                           <caption>Table 13. Effect of Cabotegravir on the Pharmacokinetics of Coadministered Drugs</caption>
                           <col width="25%"/>
                           <col width="16%"/>
                           <col width="5%"/>
                           <col width="25%"/>
                           <col width="16%"/>
                           <col width="14%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6" valign="top">n = Maximum number of participants with data, CI = Confidence Interval; NA = Not available.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Coadministered Drug(s)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">and Dose(s)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of Cabotegravir</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Geometric Mean Ratio (90% CI) of Pharmacokinetic Parameters of Coadministered Drug with/without Cabotegravir</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">No Effect = 1.00</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">AUC</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>tau</sub> or C<sub>24</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Ethinyl estradiol</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.92</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.02</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.00</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    0.03 mg once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.83, 1.03)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.97, 1.08)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.92, 1.10)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Levonorgestrel</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.05</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.07</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    0.15 mg once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.96, 1.15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(1.07, 1.18)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(1.01, 1.15)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Midazolam</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.09</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>NA</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>    3 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.94, 1.26)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.95, 1.26)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Rilpivirine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>30 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.96</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.99</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.92</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>    25 mg once daily</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>once daily</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.85, 1.09)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.89, 1.09)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.79, 1.07)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_46262e20-28f1-48a4-bee0-22d72cfcc877">
                     <id root="724d28e6-08c8-4588-85e5-b70483878ccd"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is essential for the HIV replication cycle. The mean 50% inhibitory concentration (IC<sub>50</sub>) value of cabotegravir in a strand transfer assay using purified recombinant HIV-1 integrase was 3.0 nM.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antiviral Activity in Cell Culture</content>
                        </paragraph>
                        <paragraph>Cabotegravir exhibited antiviral activity against laboratory strains of HIV-1 (subtype B, n = 4) with mean 50 percent effective concentration (EC<sub>50</sub>) values of 0.22 to 1.7 nM in peripheral blood mononuclear cells (PBMCs) and 293 cells. Cabotegravir demonstrated antiviral activity in PBMCs against a panel of 24 HIV-1 clinical isolates (3 in each of group M subtypes A, B, C, D, E, F, and G and 3 in group O) with a median EC<sub>50</sub> value of 0.19 nM (range: 0.02 to 1.06 nM, n = 24). The median EC<sub>50</sub> value against subtype B clinical isolates was 0.05 nM (range: 0.02 to 0.50 nM, n = 3). Against clinical HIV-2 isolates, the median EC<sub>50</sub> value was 0.12 nM (range: 0.10 to 0.14 nM, n = 3). </paragraph>
                        <paragraph>In cell culture, cabotegravir was not antagonistic in combination with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, or the nucleoside reverse transcriptase inhibitors (NRTIs) FTC, lamivudine (3TC), or TDF.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cell Culture:</content> Cabotegravir-resistant viruses were selected during passage of HIV-1 strain IIIB in MT-2 cells in the presence of cabotegravir. Amino acid substitutions in integrase that emerged and conferred decreased susceptibility to cabotegravir included Q146L (fold change: 1.3 to 4.6), S153Y (fold change: 2.8 to 8.4), and I162M (fold change: 2.8). The integrase substitution T124A also emerged alone (fold change: 1.1 to 7.4 in cabotegravir susceptibility), in combination with S153Y (fold change: 3.6 to 6.6 in cabotegravir susceptibility) or I162M (2.8-fold change in cabotegravir susceptibility). Cell culture passage of virus harboring integrase substitutions Q148H, Q148K, or Q148R selected for additional substitutions (C56S, V72I, L74M, V75A, T122N, E138K, G140S, G149A, and M154I), with substituted viruses having reduced susceptibility to cabotegravir of 2.0- to 410-fold change. The combinations of E138K+Q148K and V72I+E138K+Q148K conferred the greatest reductions of 53- to 260‑fold change and 410‑fold change, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Trials: </content>There were 12 incident infections and 4 prevalent infections among participants in the APRETUDE arm of HPTN 083. Genotypic data were generated for viruses from 13 of these 16 participants (4 participants with prevalent infections and 9 participants with incident infections) and phenotypic data were generated for 3 of these viruses. INSTI resistance-associated substitutions were detected in 5 viruses from participants who achieved target plasma concentrations of cabotegravir (≥0.65 mcg/mL [1.6 μM]) and included R263K (2-fold less susceptible to cabotegravir), E138A+Q148R (6-fold less susceptible to cabotegravir), E138K+Q148K, G140A+Q148R (13-fold less susceptible to cabotegravir), and L74I+E138E/K+G140G/S+Q148R+E157Q.</paragraph>
                        <paragraph>There were 3 incident infections and 1 prevalent infection among participants in the APRETUDE arm of HPTN 084. All 3 incident infections occurred during periods with cabotegravir exposures below the target concentration. No variants expressing INSTI resistance-associated substitutions were detected.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cross-Resistance</content>
                        </paragraph>
                        <paragraph>Cross-resistance has been observed among INSTIs. Cabotegravir had reduced susceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the following integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M, E92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R, Y143H+N155H, and Q148R+N155H (range: 5.1- to 81-fold). The substitutions E138K+Q148K and Q148R+N155H conferred the greatest reductions in susceptibility of 81- and 61-fold, respectively.</paragraph>
                        <paragraph>Virologic failure isolates from cabotegravir plus rilpivirine treatment in FLAIR, ATLAS, and ATLAS-2M exhibited cross-resistance to INSTIs and NNRTIs. All confirmed virologic isolates with genotypic evidence of cabotegravir resistance had cross-resistance to elvitegravir and raltegravir but retained phenotypic susceptibility to dolutegravir and when tested bictegravir. </paragraph>
                        <paragraph>Viruses harboring E138A+Q148R or G140A+Q148R with reduced susceptibility to cabotegravir were isolated from participants using APRETUDE in HPTN 083. These viruses remained susceptible to bictegravir and dolutegravir but had cross-resistance to elvitegravir and raltegravir.</paragraph>
                     </text>
                     <effectiveTime value="20240920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_be39a065-1b45-473d-8da6-26a2f1c6d7b5">
               <id root="5af9a5f4-74c4-4484-b09f-8383fcc9b216"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20230227"/>
               <component>
                  <section ID="ID_af3dbc4c-1040-4e27-a1b3-4345a2ebdfbc">
                     <id root="3effb002-b431-44fe-9824-5c17bbbe55c3"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Two-year carcinogenicity studies in mice and rats were conducted with cabotegravir. In mice, no drug-related increases in tumor incidence were observed at cabotegravir exposures (AUC) up to approximately 8 times (males) and 7 times (females) higher than those in humans at the RHD. In rats, no drug-related increases in tumor incidence were observed at cabotegravir exposures up to approximately 26 times higher than those in humans at the RHD.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Cabotegravir was not genotoxic in the bacterial reverse mutation assay, mouse lymphoma assay, or in the in vivo rodent micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>In rats, no effects on fertility were observed at cabotegravir exposures (AUC) &gt;20 times (male) and 28 times (female) the exposure in humans at the RHD.</paragraph>
                     </text>
                     <effectiveTime value="20230227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a2396e75-47f6-456b-af7b-bedec3752285">
               <id root="bca4fabe-7e85-4932-b4d8-18976dabfea1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20240920"/>
               <component>
                  <section ID="ID_0b581734-cb2d-4edd-86ec-c3c2585021b9">
                     <id root="b8e880fc-0b3f-4009-964d-f3cb7eec391a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Clinical Trials in Adults for HIV-1 Pre-Exposure Prophylaxis</title>
                     <text>
                        <paragraph>The safety and efficacy of APRETUDE to reduce the risk of acquiring HIV-1 infection were evaluated in 2 randomized, double-blind, controlled, multinational trials, HPTN 083 in men and transgender women without HIV-1 who have sex with men and have evidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women without HIV-1 at risk of acquiring HIV-1.</paragraph>
                        <paragraph>Participants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral cabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE 600‑mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months thereafter and a daily placebo tablet. Participants randomized to receive TRUVADA initiated oral TRUVADA (TDF 300 mg/FTC 200 mg) and placebo daily for up to 5 weeks, followed by oral TRUVADA daily and placebo intramuscular injection at months 1 and 2 and every 2 months thereafter.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Trial 201738 (HPTN 083 [NCT02720094])</content>
                        </paragraph>
                        <paragraph>In HPTN 083, a non-inferiority study, 4,566 cisgender men and transgender women who have sex with men were randomized 1:1 and received either APRETUDE (n = 2,281) or TRUVADA (n = 2,285) as blinded study medication up to Week 153.</paragraph>
                        <paragraph>At baseline, the median age of participants was 26 years, 12% were transgender women, 72% were non-White, and 67% were younger than 30 years.</paragraph>
                        <paragraph>The primary endpoint was the rate of incident HIV-1 infections among participants randomized to daily oral cabotegravir and intramuscular injections of APRETUDE every 2 months compared with daily oral TRUVADA (corrected for early stopping). The primary analysis demonstrated the superiority of APRETUDE compared with TRUVADA with a 66% reduction in the risk of acquiring HIV-1 infection, hazard ratio (95% CI) 0.34 (0.18, 0.62); further testing revealed 1 of the infections on APRETUDE to be prevalent then yielding a 69% reduction in the risk of HIV-1 incident infection relative to TRUVADA (<linkHtml href="#_RefTable_14">Table 14</linkHtml>).</paragraph>
                        <table ID="_RefTable_14" width="100%">
                           <caption>Table 14. HIV-1 Infection Results During Randomized Phase in HPTN 083: Extended Retrospective Virologic Testing with Readjudicated Endpoints<sup>a</sup>
                           </caption>
                           <col width="30%"/>
                           <col width="23%"/>
                           <col width="23%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4" valign="top">
                                    <sup>a</sup> mITT from Supplemental Virology Report.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4" valign="top">
                                    <sup>b</sup> Following the primary analysis, extended retrospective virologic testing was performed to better characterize the timing of HIV-1 infections. As a result, 1 of the 13 HIV-1 incident infections in participants receiving APRETUDE was determined to be a prevalent infection. The original hazard ratio (95% CI) from the primary analysis is 0.34 (0.18, 0.62).</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="bottom"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 2,278)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 2,281)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Superiority <content styleCode="italics">P</content> Value</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Person-years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3,211</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3,193</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>HIV-1 infections (incidence rate per 100 person-years)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12<sup>b</sup> (0.37)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>39 (1.22)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Hazard ratio (95% CI)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0.31 (0.16, 0.58)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0.0003</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Cumulative Incidence of HIV-1 Infections in HPTN 083 </content>
                        </paragraph>
                        <renderMultiMedia ID="id1369576491" referencedObject="FF1D206F-5C61-4FC6-9806-489A0F2F166C"/>
                        <paragraph>Results from all subgroup analyses were consistent with the overall protective effect. A lower rate of incident HIV‑1 infections was observed for participants randomized to APRETUDE compared with participants randomized to TRUVADA (<linkHtml href="#_RefTable_15">Table 15</linkHtml>). </paragraph>
                        <table ID="_RefTable_15" width="100%">
                           <caption>Table 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended Retrospective Virologic Testing with Readjudicated Endpoints<sup>a</sup>
                           </caption>
                           <col width="15%"/>
                           <col width="19%"/>
                           <col width="19%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="15%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6" valign="top">
                                    <sup>a</sup> mITT from Supplemental Virology Report. <br/>
                                    <sup>b</sup> Cisgender men who have sex with men.<br/>
                                    <sup>c</sup> Transgender women who have sex with men.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Subgroup</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE Incidence per 100 Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Incidence per 100 Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Hazard Ratio</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Age</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>&lt;30 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.47</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2,110</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.66</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,987</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.29</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.15, 0.59)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>≥30 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,101</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.50</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,206</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.39</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.08, 1.84)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Gender</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>MSM<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.35</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2,836</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2,803</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.32</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.16, 0.64)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>TGW<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.54</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>371</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.80</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>389</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.34</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.08, 1.56)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Race (US)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Black</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.58</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>691</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.28</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>703</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.26</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.09, 0.76)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Non-Black</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.00</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>836</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.50</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>801</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.11</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.00, 2.80)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Region</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>US</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.26</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,528</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.33</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,504</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.21</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.07, 0.60)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Latin America</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.49</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,020</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.09</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,011</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.47</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.17, 1.35)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Asia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.35</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>570</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.03</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>581</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.39</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.08, 1.82)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>Africa</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.08</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>93</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.07</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>97</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.63</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.06, 6.50)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Trial 201739 (HPTN 084 [NCT03164564])</content>
                        </paragraph>
                        <paragraph>In HPTN 084, a superiority study, 3,224 cisgender women were randomized 1:1 and received either APRETUDE (n = 1,614) or TRUVADA (n = 1,610) as blinded study medication up to Week 153.</paragraph>
                        <paragraph>At baseline, the median age of participants was 25 years, &gt;99% were non-White, &gt;99% were cisgender women, and 49% were &lt;25 years of age. </paragraph>
                        <paragraph>The primary endpoint was the rate of incident HIV-1 infections among participants randomized to oral cabotegravir and injections of APRETUDE compared with oral TRUVADA (corrected for early stopping). The primary analysis demonstrated the superiority of APRETUDE compared with TRUVADA with an 88% reduction in the risk of acquiring incident HIV-1 infection, hazard ratio (95% CI) 0.12 (0.05, 0.31); further testing revealed 1 of the infections on APRETUDE to be prevalent then yielding a 90% reduction in the risk of HIV-1 incident infection relative to TRUVADA (<linkHtml href="#_RefTable_16">Table 16</linkHtml>).</paragraph>
                        <table ID="_RefTable_16" width="100%">
                           <caption>Table 16. HIV-1 Infection Results during Randomized Phase in HPTN 084: Extended Retrospective Virologic Testing with Readjudicated Endpoints<sup>a</sup>
                           </caption>
                           <col width="31%"/>
                           <col width="23%"/>
                           <col width="23%"/>
                           <col width="23%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4" valign="top">
                                    <sup>a</sup> mITT from Supplemental Virology Report.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4" valign="top">
                                    <sup>b </sup>Following the primary analysis, extended retrospective virologic testing was performed to better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1 incident infections in participants receiving APRETUDE was determined to be a prevalent infection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05, 0.31).</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 1,613)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 1,610)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Superiority</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="italics">P</content> Value</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Person-years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,960</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,946</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>HIV-1 incident infections (incidence rate per 100 person-years)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3<sup>b</sup> (0.15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>36 (1.85)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Hazard ratio (95% CI)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0.10 (0.04, 0.27)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>&lt;0.0001</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 2. Cumulative Incidence of HIV-1 Infections in HPTN 084</content>
                        </paragraph>
                        <renderMultiMedia ID="id2068759281" referencedObject="FDBCEAA2-F989-4995-8515-200BD4FC0802"/>
                        <paragraph>Results from pre-planned subgroup analyses were consistent with the overall protective effect. A lower rate of incident HIV-1 infections was observed for participants randomized to APRETUDE compared with participants randomized to TRUVADA (<linkHtml href="#_RefTable_17">Table 17</linkHtml>).</paragraph>
                        <table ID="_RefTable_17" width="100%">
                           <caption>Table 17. Incident of HIV-1 Infections by Subgroup in HPTN 084: Extended Retrospective Virologic Testing with Readjudicated Endpoints<sup>a</sup>
                           </caption>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6" valign="top">
                                    <sup>a</sup> mITT from Supplemental Virology Report.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Subgroup</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE Incidence</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">per 100 Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">APRETUDE Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA Incidence</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">per 100 Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">TRUVADA Person-Years</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Hazard Ratio</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(95% CI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Age</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>&lt;25 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.23</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>868</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>2.34</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>853</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.12</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.03, 0.46)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>≥25 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.09</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,093</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.46</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,093</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.09</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.02, 0.49)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body Mass Index</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>&lt;30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,385</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.88</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1,435</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.12</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>(0.04, 0.38)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule " valign="top">
                                    <paragraph>≥30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.00</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>575</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>1.76</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>511</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule " valign="top">
                                    <paragraph>0.04</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>(0.00, 0.93)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240920"/>
                     <component>
                        <observationMedia ID="FF1D206F-5C61-4FC6-9806-489A0F2F166C">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="apretude-spl-graphic-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="FDBCEAA2-F989-4995-8515-200BD4FC0802">
                           <text>Figure 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="apretude-spl-graphic-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_69ae0649-5e98-4378-a58c-96ae69be2387">
               <id root="8fe7c5cd-a137-4c92-926c-26a41f114c84"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>APRETUDE is supplied in a kit containing one 600-mg/3-mL single-dose (200-mg/mL) vial of cabotegravir extended-release injectable suspension, 1 syringe, 1 vial adapter, and 1 needle for intramuscular injection (23 gauge, 1½ inch) (NDC 49702-264-23). The vial stopper is not made with natural rubber latex.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store APRETUDE at 2°C to 25°C (36°F to 77°F) in the original carton until ready to use. Exposure up to 30°C permitted. Do not freeze. Do not mix with any other product or diluent.</paragraph>
                  <paragraph>If the pack has been stored in the refrigerator, the vial should be brought to room temperature prior to administration (not to exceed 30°C [86°F]). </paragraph>
                  <paragraph>Once the suspension has been drawn into the syringe, the injection should be administered as soon as possible, but may remain in the syringe for up to 2 hours. The filled syringes should not be placed in the refrigerator. If the medicine remains in the syringe for more than 2 hours, the filled syringe and needle must be discarded <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_debb9a3b-2f0e-4ddd-9073-822e600d3ae0">2.7</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20230227"/>
            </section>
         </component>
         <component>
            <section ID="ID_da48ff90-8088-407c-a029-c60640b4ca6a">
               <id root="52effafc-47cc-4de7-8c5f-5298d5e3d153"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the individual to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Information for Individuals without HIV-1 Taking APRETUDE for HIV-1 Pre</content>‑<content styleCode="underline">Exposure Prophylaxis</content>
                  </paragraph>
                  <paragraph>Advise individuals without HIV-1 about the following <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>APRETUDE should be used for PrEP as part of an overall HIV-1 infection prevention strategy, including adherence to the administration schedule and safer sex practices, including condoms, to reduce the risk of STIs.</item>
                     <item>
                        <caption>•</caption>APRETUDE is not always effective in preventing HIV-1 acquisition <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0b581734-cb2d-4edd-86ec-c3c2585021b9">14.1</linkHtml>)]</content>. The time from initiation of APRETUDE for HIV-1 PrEP to maximal protection against HIV-1 infection is unknown.</item>
                     <item>
                        <caption>•</caption>Counsel individuals on the use of other prevention measures (e.g., knowledge of partner HIV-1 status, testing for STIs condom use). Inform individuals about and support their efforts in reducing sexual risk behavior.</item>
                     <item>
                        <caption>•</caption>APRETUDE should be used to reduce the risk of acquiring HIV-1 only in individuals confirmed to be HIV-1 negative <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>. HIV-1 resistance substitutions may emerge in individuals with undiagnosed HIV-1 infection who are taking only APRETUDE, because APRETUDE alone does not constitute a complete regimen for HIV-1 treatment; therefore, care should be taken to minimize the risk of initiating or continuing APRETUDE before confirming the individual is HIV-1 negative. </item>
                     <item>
                        <caption>•</caption>If recent (&lt;1 month) exposures to HIV-1 are suspected or clinical symptoms consistent with acute HIV-1 infection are present, use a test approved or cleared by the FDA as an aid in the diagnosis of acute or primary HIV-1 infection.</item>
                     <item>
                        <caption>•</caption>When using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each injection of APRETUDE, and upon diagnosis of any other STIs. </item>
                     <item>
                        <caption>•</caption>If an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent with acute HIV-1 infection develop following an exposure event, additional HIV testing to determine HIV status is needed. If an individual has confirmed HIV-1 infection, then the individual must be transitioned to a complete HIV-1 treatment regimen.</item>
                     <item>
                        <caption>•</caption>Some individuals, such as adolescents, may benefit from frequent visits and counseling to support adherence.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Potential Risk of Resistance with APRETUDE</content>
                  </paragraph>
                  <paragraph>Advise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1 is acquired either before or while taking APRETUDE or following discontinuation of APRETUDE <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>To minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1 acquisition and tested frequently to confirm HIV-1 negative status. Advise individuals who are confirmed to have with HIV-1 infection to consult with their healthcare professional, as HIV-1 treatment must be initiated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>Inform individuals that alternative forms of PrEP should be considered following discontinuation of APRETUDE for those at continuing risk of HIV-1 acquisition and initiated within 2 months of the final injection of APRETUDE <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_da0f3de2-3a8c-4cf2-9e2f-6eeb16e4f851">5.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Long-Acting Properties of APRETUDE</content>
                  </paragraph>
                  <paragraph>Advise individuals that APRETUDE is an extended-release injectable that may be systemically present for 12 months or longer and consideration should be taken regarding the prolonged release characteristics when APRETUDE is discontinued <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>), Drug Interactions (<linkHtml href="#ID_2759f01b-6e1e-457a-b703-ffceb8a88a43">7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Adherence to APRETUDE</content>
                  </paragraph>
                  <paragraph>Counsel individuals about the importance of continued medication adherence and scheduled visits to help reduce the risk of acquiring HIV-1 infection and development of resistance <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_bd42e99d-60aa-448e-b46f-7a843ce41b0a">2.3</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_4b0811ab-1110-42f7-a018-8eb50e893cc0">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions </content>
                  </paragraph>
                  <paragraph>Advise individuals to immediately contact their healthcare provider if they develop a rash. Instruct individuals to immediately stop taking APRETUDE and seek medical attention if they develop a rash associated with any of the following symptoms as it may be a sign of a more serious reaction such as Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN): fever; generally ill feeling; extreme tiredness; muscle or joint aches; blisters; oral blisters or lesions; eye inflammation; facial swelling; swelling of the eyes, lips, tongue, or mouth; difficulty breathing; and/or signs and symptoms of liver problems (e.g., yellowing of the skin or whites of the eyes; dark or tea‑colored urine; pale-colored stools or bowel movements; nausea; vomiting; loss of appetite; or pain, aching, or sensitivity on the right side below the ribs). Advise individuals that if hypersensitivity occurs, they will be closely monitored, laboratory tests will be ordered, and appropriate therapy will be initiated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_0758a7f4-0ec5-45a9-aa17-cd8af2f5355f">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Inform individuals that hepatotoxicity has been reported with cabotegravir<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID_7e73b8c5-7a44-467c-9f71-b4a17047f499">5.5</linkHtml>), Adverse Reactions (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>)]</content>. Inform individuals that clinical and laboratory monitoring should be considered and APRETUDE should be discontinued if hepatoxicity is confirmed <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7e73b8c5-7a44-467c-9f71-b4a17047f499">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Depressive Disorders</content>
                  </paragraph>
                  <paragraph>Inform individuals that depressive disorders (including depression, depressed mood, major depression, persistent depressive disorder, suicidal ideation, suicide attempt) have been reported with APRETUDE <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_cc848be4-6289-4f39-b214-512da57251ee">6.1</linkHtml>)]</content>. Advise individuals to seek prompt medical evaluation if they experience depressive symptoms <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_bff6684f-970f-4418-858a-2eeb57434723">5.6</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Inform individuals that APRETUDE may interact with other drugs and may reduce exposure of APRETUDE; therefore, advise individuals to report to their healthcare provider the use of any other prescription or nonprescription medication <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_3bcc1653-dfb0-4253-8b0b-6748f4cc2925">4</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_1e95108b-bdb6-40da-bf50-d7a75ce69908">5.7</linkHtml>), Drug Interactions (<linkHtml href="#ID_15358dc8-7a1e-4506-90c1-ccc6f22d4c18">7.2</linkHtml>, <linkHtml href="#ID_a3f14517-a64d-435d-80e5-8f30f3cbdda2">7.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Missed Dose</content>
                  </paragraph>
                  <paragraph>Inform individuals that APRETUDE can remain in the body for up to 12 months or longer after receiving their last injection. Advise individuals that they should contact their healthcare provider if they miss or plan to miss a scheduled monthly injection visit and that oral dosing may be used to replace up to 2 consecutive monthly injections. Advise individuals that if they discontinue use of APRETUDE, they will need to take other medicines for HIV-1 PrEP <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_bd42e99d-60aa-448e-b46f-7a843ce41b0a">2.3</linkHtml>, <linkHtml href="#ID_56594e75-975d-48dc-a5bf-d9d368e9141e">2.6</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy Registry</content>
                  </paragraph>
                  <paragraph>Inform individuals that there is an antiretroviral pregnancy registry to monitor fetal outcomes in those exposed to APRETUDE during pregnancy. Individuals who are of reproductive potential should be informed of the long duration of exposure of APRETUDE and that there is very limited clinical experience in human pregnancy<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#ID_126d7927-cbe8-4d7c-b3be-77ced45d9c10">5.3</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_61de2542-73e5-4ad7-b044-ad0d6c2927af">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Inform individuals that due to the potential for adverse reactions and residual concentrations in the systemic circulation for up to 12 months or longer after discontinuing injections of APRETUDE, it is recommended that mothers breastfeed only if the expected benefit justifies the potential risk to the infant. The benefits and risks of APRETUDE while breastfeeding should be evaluated, including the risk of HIV-1 acquisition due to medication nonadherence and subsequent mother to child transmission. Instruct mothers not to breastfeed if acute HIV-1 infection is suspected because of the risk of passing the HIV-1 virus to the baby <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_6cd6cd2b-7b85-467d-9e17-d55be43208e4">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>APRETUDE, CABENUVA, and VOCABRIA are trademarks owned by or licensed to the ViiV Healthcare group of companies.</paragraph>
                  <paragraph>The other brand listed is a trademark owned by or licensed to its respective owner and is not a trademark owned by or licensed to the ViiV Healthcare group of companies. The maker of this brand is not affiliated with and does not endorse the ViiV Healthcare group of companies or its products. </paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>ViiV Healthcare<br/>Durham, NC 27701</paragraph>
                  <paragraph>©2025 ViiV Healthcare group of companies or its licensor.</paragraph>
                  <paragraph>APR:5PI</paragraph>
               </text>
               <effectiveTime value="20240920"/>
            </section>
         </component>
         <component>
            <section ID="ID_a98c6b6b-c982-4f78-a6b7-f64a631953a6">
               <id root="dec082c8-75cb-4ca6-aa82-231091b9db49"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%"/>
                     <col width="47%"/>
                     <col width="50%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">APRETUDE [AP-reh-tood]</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(cabotegravir extended-release injectable suspension)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">for intramuscular use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about APRETUDE?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Important information for people who receive APRETUDE to help reduce their risk of getting human immunodeficiency virus-1 (HIV-1) infection, also called pre-exposure prophylaxis or “PrEP”:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before receiving APRETUDE to reduce your risk of getting HIV-1:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">You must be HIV-1 negative to start APRETUDE. You must get tested to make sure that you do not already have HIV-1 infection.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not receive APRETUDE for HIV-1 PrEP unless you are confirmed to be HIV-1 negative.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Some HIV-1 tests can miss HIV-1 infection in a person who has recently become infected. If you have flu-like symptoms, you could have recently become infected with HIV-1. Tell your healthcare provider if you had a flu-like illness within the last month before starting APRETUDE or at any time while receiving APRETUDE. Symptoms of new HIV-1 infection include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   tiredness</item>
                                 <item>
                                    <caption> </caption>○   joint or muscle aches</item>
                                 <item>
                                    <caption> </caption>○   sore throat</item>
                                 <item>
                                    <caption> </caption>○   rash</item>
                                 <item>
                                    <caption> </caption>○   enlarged lymph nodes in the neck or groin</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   fever</item>
                                 <item>
                                    <caption> </caption>○   headache</item>
                                 <item>
                                    <caption> </caption>○   vomiting or diarrhea</item>
                                 <item>
                                    <caption> </caption>○   night sweats</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">While you are receiving APRETUDE for HIV-1 PrEP:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">APRETUDE does not prevent other sexually transmitted infections. Practice safer sex by using a latex or polyurethane condom to reduce the risk of getting sexually transmitted infections.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">You must stay HIV-1 negative to keep receiving APRETUDE for HIV-1 PrEP.</content>
                                    <list listType="unordered">
                                       <item>
                                          <caption>o</caption>Know your HIV-1 status and the HIV-1 status of your partners.</item>
                                       <item>
                                          <caption>o</caption>Ask your partners with HIV-1 if they are taking anti-HIV-1 medicines and have an undetectable viral load. An undetectable viral load is when the amount of virus in the blood is too low to be measured in a lab test. To maintain an undetectable viral load, your partners must keep taking HIV-1 medicine as prescribed. Your risk of getting HIV-1 is lower if your partners with HIV-1 are taking effective treatment.</item>
                                       <item>
                                          <caption>o</caption>Get tested for HIV-1 with each APRETUDE injection or when your healthcare provider tells you. You should not miss any HIV-1 tests. If you become HIV-1–infected and continue receiving APRETUDE because you do not know you are HIV-1–infected, the HIV-1 infection may become harder to treat.</item>
                                       <item>
                                          <caption>o</caption>Get tested for other sexually transmitted infections such as syphilis, chlamydia, and gonorrhea. These infections make it easier for HIV-1 to infect you.</item>
                                       <item>
                                          <caption>o</caption>If you think you were exposed to HIV-1, tell your healthcare provider right away. They may want to do more tests to be sure you are still HIV-1 negative.</item>
                                       <item>
                                          <caption>o</caption>Get information and support to help reduce sexual risk behaviors.</item>
                                       <item>
                                          <caption>o</caption>Do not miss any injections of APRETUDE. Missing injections increases your risk of getting HIV-1 infection.</item>
                                       <item>
                                          <caption>o</caption>If you do become HIV-1 positive, you will need to take other medicines to treat HIV-1. APRETUDE is not approved for treatment of HIV-1.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">If you have HIV-1 and receive only APRETUDE, over time your HIV-1 may become harder to treat.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is APRETUDE?</content>
                              </paragraph>
                              <paragraph>APRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg). </paragraph>
                              <paragraph>HIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).</paragraph>
                              <paragraph>It is not known if APRETUDE is safe and effective in children younger than 12 years of age or weighing less than 77 pounds (less than 35 kg).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not receive APRETUDE if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">already have HIV-1 infection. </content>If you are HIV-1 positive, you will need to take other medicines to treat HIV-1. APRETUDE is not approved for treatment of HIV-1.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">do not know your HIV-1 infection status.</content> You may already be HIV-1 positive. You need to take other medicines to treat HIV-1. APRETUDE can only help reduce your risk of getting HIV-1 infection <content styleCode="bold">before</content> you are infected.</item>
                                 <item>
                                    <caption>•</caption>have ever had an allergic reaction to cabotegravir</item>
                                 <item>
                                    <caption>•</caption>are taking any of the following medicines:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule " valign="top"/>
                           <td styleCode="Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   carbamazepine</item>
                                 <item>
                                    <caption> </caption>○   oxcarbazepine</item>
                                 <item>
                                    <caption> </caption>○   phenobarbital</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   phenytoin</item>
                                 <item>
                                    <caption> </caption>○   rifampin</item>
                                 <item>
                                    <caption> </caption>○   rifapentine</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before receiving APRETUDE, tell your healthcare provider about all your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have ever had a skin rash or an allergic reaction to medicines that contain cabotegravir.</item>
                                 <item>
                                    <caption>•</caption>have or have had liver problems.</item>
                                 <item>
                                    <caption>•</caption>have ever had mental health problems. </item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if APRETUDE will harm your unborn baby. APRETUDE can remain in your body for up to 12 months or longer after the last injection. Tell your healthcare provider if you become pregnant while or after receiving APRETUDE.<br/>
                                    <content styleCode="bold">Pregnancy Registry.</content> There is a pregnancy registry for those who receive APRETUDE during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. APRETUDE may pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby while or after receiving APRETUDE.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Some medicines may interact with APRETUDE. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                              <paragraph>You can ask your healthcare provider or pharmacist for a list of medicines that interact with APRETUDE.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not start a new medicine without telling your healthcare provider.</content> Your healthcare provider can tell you if it is safe to receive APRETUDE with other medicines.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How will I receive APRETUDE?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>APRETUDE will be given to you as an injection by your healthcare provider.</item>
                                 <item>
                                    <caption>•</caption>APRETUDE is initially given as an injection into the muscle of your buttock 1 time every month for the first 2 months, then as an injection 1 time every 2 months.</item>
                                 <item>
                                    <caption>•</caption>Before receiving your first injection dose of APRETUDE, your healthcare provider may have you take 1 VOCABRIA (cabotegravir) tablet 1 time a day for 1 month (at least 28 days). This will allow your healthcare provider to assess how well you will tolerate cabotegravir.</item>
                                 <item>
                                    <caption>•</caption>APRETUDE is a long-acting medicine and may stay in your body for 12 months or longer after your last injection. </item>
                                 <item>
                                    <caption>•</caption>Stay under the care of a healthcare provider while receiving APRETUDE. It is important that you receive APRETUDE as scheduled.</item>
                                 <item>
                                    <caption>•</caption>If you miss or plan to miss a scheduled injection of APRETUDE by more than 7 days, call your healthcare provider right away to discuss your PrEP options.</item>
                                 <item>
                                    <caption>•</caption>If you stop receiving APRETUDE, talk to your healthcare provider about other options to reduce the risk of getting HIV-1 infection.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of APRETUDE?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">APRETUDE may cause serious side effects including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Allergic reactions.</content> Call your healthcare provider right away if you develop a rash with APRETUDE. <content styleCode="bold">Stop receiving APRETUDE and get medical help right away if you develop a rash with any of the following signs or symptoms:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   fever</item>
                                 <item>
                                    <caption> </caption>○   generally ill feeling</item>
                                 <item>
                                    <caption> </caption>○   tiredness</item>
                                 <item>
                                    <caption> </caption>○   muscle or joint aches</item>
                                 <item>
                                    <caption> </caption>○   trouble breathing</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   blisters or sores in mouth </item>
                                 <item>
                                    <caption> </caption>○   blisters</item>
                                 <item>
                                    <caption> </caption>○   redness or swelling of the eyes</item>
                                 <item>
                                    <caption> </caption>○   swelling of the mouth, face, lips, or tongue</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Liver problems.</content> Liver problems have happened in people with or without a history of liver problems or other risk factors. Your healthcare provider may do blood tests to check your liver function. <br/>
                                    <content styleCode="bold">Call your healthcare provider right away if you develop any of the following signs or symptoms of liver problems:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○   your skin or the white part of your eyes turns yellow (jaundice)</item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   dark or “tea-colored” urine</item>
                                 <item>
                                    <caption> </caption>○   light-colored stools (bowel movements)</item>
                                 <item>
                                    <caption> </caption>○   nausea or vomiting</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   loss of appetite</item>
                              </list>
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>○   pain, aching, or tenderness on the right side of your stomach area</item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>○   itching</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Depression or mood changes. Call your healthcare provider or get medical help right away if you develop any of the following symptoms:</content>
                                    <paragraph>○   feeling sad or hopeless</paragraph>
                                    <paragraph>○   feeling anxious or restless </paragraph>
                                    <paragraph>○   have thoughts of hurting yourself (suicide) or have tried to hurt yourself</paragraph>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of APRETUDE include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>pain, tenderness, hardened mass or lump, swelling, bruising, redness, itching, warmth, loss of sensation at the injection site, abscess, and discoloration</item>
                                 <item>
                                    <caption>•</caption>diarrhea</item>
                                 <item>
                                    <caption>•</caption>headache</item>
                                 <item>
                                    <caption>•</caption>fever</item>
                                 <item>
                                    <caption>•</caption>tiredness</item>
                                 <item>
                                    <caption>•</caption>sleep problems</item>
                                 <item>
                                    <caption>•</caption>nausea</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>dizziness</item>
                                 <item>
                                    <caption>•</caption>passing gas</item>
                                 <item>
                                    <caption>•</caption>stomach pain</item>
                                 <item>
                                    <caption>•</caption>vomiting</item>
                                 <item>
                                    <caption>•</caption>muscle pain</item>
                                 <item>
                                    <caption>•</caption>rash</item>
                                 <item>
                                    <caption>•</caption>loss of appetite</item>
                                 <item>
                                    <caption>•</caption>drowsiness</item>
                                 <item>
                                    <caption>•</caption>back pain</item>
                                 <item>
                                    <caption>•</caption>upper respiratory infection</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>These are not all the possible side effects of APRETUDE. </paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of APRETUDE.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about APRETUDE that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in APRETUDE?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient: </content>cabotegravir</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> mannitol, polyethylene glycol (PEG) 3350, polysorbate 20, and Water for Injection.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Manufactured for:</paragraph>
                              <paragraph>ViiV Healthcare</paragraph>
                              <paragraph>Durham, NC 27701</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>APRETUDE and VOCABRIA are trademarks owned by or licensed to the ViiV Healthcare group of companies.</paragraph>
                              <paragraph>©2025 ViiV Healthcare group of companies or its licensor.</paragraph>
                              <paragraph>APR:5PIL</paragraph>
                              <paragraph>For more information, go to <linkHtml href="http://www.apretude.com">www.apretude.com</linkHtml> or call 1-877-844-8872.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>This Patient Information has been approved by the U.S. Food and Drug Administration.               Revised: 4/2025</item>
                  </list>
               </text>
               <effectiveTime value="20240920"/>
            </section>
         </component>
         <component>
            <section ID="ID_eb073384-637d-410a-9e85-3bdbd6c06b69">
               <id root="e2bc182e-7f5f-4080-b422-cdfb87f8a5c9"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="69%"/>
                     <col width="31%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <renderMultiMedia ID="id229349695" referencedObject="AE46A390-5BED-4676-8B4F-5CD01EF822C8"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Overview:</content>
                              </paragraph>
                              <paragraph>A complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.</paragraph>
                              <paragraph>APRETUDE is a suspension that does not need further dilution or reconstitution. Carefully follow these instructions when preparing the suspension for injection to avoid leakage.</paragraph>
                              <paragraph>APRETUDE is for gluteal intramuscular use only.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Note:</content> The ventrogluteal site is recommended.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <renderMultiMedia ID="id2116856876" referencedObject="ID_1d73cff2-e068-480a-a7ad-9dc4de9762ed"/>
                                 <content styleCode="bold"> Storage information</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Store at 2°C to 25°C (36°F to 77°F). Exposure up to 30°C (86°F) permitted.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not </content>freeze.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Prior to administration:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>If the pack has been stored in the refrigerator, the vial should be brought to room temperature prior to administration (not to exceed 30°C [86°F]).</item>
                                 <item>
                                    <caption>•</caption>Once APRETUDE has been drawn into the syringe, the medicine can remain in the syringe for up to 2 hours before injection. The filled syringe should not be placed in the refrigerator. If the medicine remains in the syringe for more than 2 hours, the filled syringe and needle must be discarded.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1798057260" referencedObject="ID_46a94cca-40db-44f2-a120-16f2a110d44f"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Your pack contains:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>1 vial of APRETUDE</item>
                                 <item>
                                    <caption>•</caption>1 vial adapter</item>
                                 <item>
                                    <caption>•</caption>1 syringe</item>
                                 <item>
                                    <caption>•</caption>1 injection needle (23 gauge, 1½ inch) </item>
                              </list>
                              <paragraph>Consider the individual’s build and use medical judgment to select an appropriate injection needle length.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">You will also need:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Non-sterile gloves </item>
                                 <item>
                                    <caption>•</caption>2 alcohol wipes </item>
                                 <item>
                                    <caption>•</caption>2 gauze pads</item>
                                 <item>
                                    <caption>•</caption>A suitable sharps container</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Preparation:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">1. Inspect the vial.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-203090696" referencedObject="ID_2e73283f-fd90-4d22-9050-41d58e690bb9"/>
                              <paragraph>
                                 <content styleCode="bold">Figure A</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Check that the expiration date has not passed. <content styleCode="bold">See Figure A.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Inspect the vial immediately. If you can see foreign matter, do not use the product.</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Note:</content> The vial has a brown tint to the glass.</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Do not</content> use if the expiration date has passed.</item>
                                 <item>
                                    <caption>•</caption>If the pack has been stored in the refrigerator, allow the medication to come to room temperature.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">2. Shake the vial vigorously.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id2084026179" referencedObject="ID_3c56771c-f1b0-43d1-9f84-3d0f5e770300"/>
                              <paragraph>
                                 <content styleCode="bold">Figure B</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Hold the vial firmly, and vigorously shake for a full 10 seconds. <content styleCode="bold">See Figure B.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">3. Inspect suspension.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id282459184" referencedObject="ID_5f40754e-cbff-4a51-b818-ad0cc9a9d6bf"/>
                              <paragraph>
                                 <content styleCode="bold">Figure C</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Invert the vial and confirm the suspension is uniform. It should look uniform. <content styleCode="bold">See Figure C.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>If the suspension is not uniform, shake the vial again.</item>
                                 <item>
                                    <caption>•</caption>It is also normal to see small air bubbles.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">4. Remove the vial cap.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id548728332" referencedObject="ID_54360fae-fb0e-4b7a-a1e0-d3190a4c9057"/>
                              <paragraph>
                                 <content styleCode="bold">Figure D</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Remove the cap from the vial. <content styleCode="bold">See Figure D.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Wipe the rubber stopper with an alcohol wipe. </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Do not</content> allow anything to touch the rubber stopper after wiping it.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">5. Peel open the vial adapter.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1189723626" referencedObject="AB9CD7CB-81B6-45E1-B158-BE8D9F23E338"/>
                              <paragraph>
                                 <content styleCode="bold">Figure E</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Peel off the paper backing from the vial adapter packaging. <content styleCode="bold">See Figure E.</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Note:</content> Do not remove the adapter from its packaging for the next step. The adapter <content styleCode="bold">will not</content> fall out when its packaging is turned upside down.</item>
                                 <item>
                                    <caption> </caption>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">6. Place vial on flat surface and attach the vial adapter.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1231218679" referencedObject="ID_17e78c2d-b1ed-48cc-9ceb-ba8aac49f39e"/>
                              <paragraph>
                                 <content styleCode="bold">Figure F</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Ensure the vial is upright and on a flat surface. <content styleCode="bold">See Figure F.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Press the vial adapter straight down onto the vial, as shown.</item>
                                 <item>
                                    <caption>•</caption>The vial adapter should click securely into place.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">7. Lift off the packaging.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1706906927" referencedObject="ID_399c6b03-640e-4b95-bbed-887501e7f76d"/>
                              <paragraph>
                                 <content styleCode="bold">Figure G</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Lift off the vial adapter packaging, as shown.<content styleCode="bold"> See Figure G.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">8. Prepare the syringe.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1994796004" referencedObject="ID_646d1857-31a6-4d6a-86e0-f9c11be967e8"/>
                              <paragraph>
                                 <content styleCode="bold">Figure H</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Remove the syringe from its packaging.</item>
                                 <item>
                                    <caption>•</caption>Draw 1 mL of air into the syringe. This will make it easier to draw up the medicine later. <content styleCode="bold">See Figure H.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">9. Attach the syringe.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1949998177" referencedObject="AC7C48A7-671F-4302-B1F5-13C2483A566E"/>
                              <paragraph>
                                 <content styleCode="bold">Figure I</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Hold the vial adapter and vial firmly, as shown.</item>
                                 <item>
                                    <caption>•</caption>Screw the syringe firmly onto the vial adapter. <content styleCode="bold">See Figure I.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">10. Press the plunger.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-147441965" referencedObject="E7B0D59D-E89B-4652-9FD7-5AA410703AC4"/>
                              <paragraph>
                                 <content styleCode="bold">Figure J</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Press the plunger all the way down to push the air into the vial. <content styleCode="bold">See Figure J.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">11. Slowly draw up the dose.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1160689931" referencedObject="ID_8ce9bb92-c57f-40cb-a42b-ddd486bc5174"/>
                              <paragraph>
                                 <content styleCode="bold">Figure K</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Invert the syringe and vial and slowly withdraw as much of the medicine as possible into the syringe. There may be more medicine than the dose amount. <content styleCode="bold">See Figure K.</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Note:</content> Keep the syringe upright to avoid leakage.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">12. Unscrew the syringe.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id774209232" referencedObject="ID_142efe88-ec6b-43a5-9bad-89d2cd7c8005"/>
                              <paragraph>
                                 <content styleCode="bold">Figure L</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Hold the syringe plunger firmly in place as shown to prevent leakage. It is normal to feel some back pressure.</item>
                                 <item>
                                    <caption>•</caption>Unscrew the syringe from the vial adapter, holding the vial adapter as shown. <content styleCode="bold">See Figure L.</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Note:</content> Check that the suspension looks uniform and milky white.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">13. Attach the needle.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id2030066739" referencedObject="ID_5ee44e9e-4275-4db8-82ba-53a426eaa8c7"/>
                              <paragraph>
                                 <content styleCode="bold">Figure M</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Peel open the needle packaging part way to expose the needle base.</item>
                                 <item>
                                    <caption>•</caption>Keeping the syringe upright, firmly twist the syringe onto the needle. </item>
                                 <item>
                                    <caption>•</caption>Remove the needle packaging from the needle. <content styleCode="bold">See Figure M.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Injection:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">14. Prepare the injection site.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-547227573" referencedObject="B144C58F-EC4E-4C7F-A762-949B92E8986A"/>
                              <paragraph>
                                 <content styleCode="bold">Figure N</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>APRETUDE must be administered to a gluteal site. <content styleCode="bold">See Figure N</content>.</item>
                                 <item>
                                    <caption> </caption>Select from the following areas for the injection:</item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Ventrogluteal, as shown (recommended)</item>
                                 <item>
                                    <caption>•</caption>Dorsogluteal, not shown (upper outer quadrant)</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Note: </content>For gluteal intramuscular use only.<br/>
                                    <content styleCode="bold">Do not</content> inject intravenously.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">15. Remove the cap.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id2125496266" referencedObject="BF84167A-96D2-4AE7-8B46-21D2F4D2F029"/>
                              <paragraph>
                                 <content styleCode="bold">Figure O</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Fold the needle guard away from the needle. <content styleCode="bold">See Figure O.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Pull off the injection needle cap.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">16. Remove extra liquid from the syringe.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1473947728" referencedObject="ID_4d09a3d0-3080-4ac8-9540-50d24af19a3e"/>
                              <paragraph>
                                 <content styleCode="bold">Figure P</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Hold the syringe with the needle pointing up. Press the plunger to the 3 mL dosing mark to remove extra liquid and any air bubbles. <content styleCode="bold">See Figure P.</content>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Note:</content> Clean the injection site with an alcohol wipe. Allow the skin to air dry before continuing.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">17. Stretch the skin.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id2018657717" referencedObject="ID_13ccf563-323b-435b-9302-66e9b34ce64f"/>
                              <paragraph>
                                 <content styleCode="bold">Figure Q</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>Use the z-track injection technique to minimize medicine leakage from the injection site.</item>
                              </list>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Firmly drag the skin covering the injection site, displacing it by about an inch (2.5 cm). <content styleCode="bold">See Figure Q.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Keep it held in this position for the injection.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">18. Insert the needle.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-1441684898" referencedObject="F59CFF8C-3C17-4218-8949-276667545FC7"/>
                              <paragraph>
                                 <content styleCode="bold">Figure R</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Insert the needle to its full depth, or deep enough to reach the muscle. <content styleCode="bold">See Figure R.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">19. Inject the dose of medicine.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1042252430" referencedObject="ID_44979507-6ee4-449f-b4a7-dad655ef3e4e"/>
                              <paragraph>
                                 <content styleCode="bold">Figure S</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Still holding the skin stretched – slowly press the plunger all the way down. <content styleCode="bold">See Figure S.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Ensure the syringe is empty.</item>
                                 <item>
                                    <caption>•</caption>Withdraw the needle and release the stretched skin immediately.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">20. Assess the injection site.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-554157893" referencedObject="DE9628A5-E2A2-45C4-B8D6-C0E64A1BC1D5"/>
                              <paragraph>
                                 <content styleCode="bold">Figure T</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Apply pressure to the injection site using a gauze pad. <content styleCode="bold">See Figure T.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>A small bandage may be used if bleeding occurs.</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Do not</content> massage the area.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">21. Make the needle safe.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1486584380" referencedObject="BAF69D69-033A-4E01-955D-76192A35EDB1"/>
                              <paragraph>
                                 <content styleCode="bold">Figure U</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Fold the needle guard over the needle. <content styleCode="bold">See Figure U.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1805812036" referencedObject="BD95C5A6-DA23-469D-A2FC-2CEC0FB9089C"/>
                              <paragraph>
                                 <content styleCode="bold">Figure V</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Gently apply pressure using a hard surface to lock the needle guard in place.</item>
                                 <item>
                                    <caption>•</caption>The needle guard will make a click when it locks. <content styleCode="bold">See Figure V.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">After injection:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">22. Dispose safely.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id1599445454" referencedObject="ID_5513cc9c-5b5c-4600-885f-21f3f54d61a4"/>
                              <paragraph>
                                 <content styleCode="bold">Figure W</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Dispose of used needle, syringe, vial, and vial adapter according to local health and safety laws. <content styleCode="bold">See Figure W.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Questions and Answers</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption>1.</caption>
                                    <content styleCode="bold">If the pack has been stored in the refrigerator, is it safe to warm the vial up to room temperature more quickly?</content>
                                    <br/>The vial should be brought to room temperature before you are ready to give the injection, but make sure the vial does not get above 30°C (86°F).</item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Do not</content> use any heating methods, other than using the warmth of your hands.</item>
                                 <item>
                                    <caption>2.</caption>
                                    <content styleCode="bold">How long can APRETUDE be left in the syringe?</content>
                                    <br/>It is best to inject (room temperature) APRETUDE as soon as possible after drawing it up. However, APRETUDE can remain in the syringe for up to 2 hours before injection.<br/>If the medicine remains in the syringe for more than 2 hours, the filled syringe and needle must be discarded.</item>
                                 <item>
                                    <caption>3.</caption>
                                    <content styleCode="bold">Why do I need to inject air into the vial?</content>
                                    <br/>Injecting 1 mL of air into the vial makes it easier to draw up the medicine into the syringe. Without the air, some liquid may flow back into the vial unintentionally, leaving less medicine than intended in the syringe.</item>
                                 <item>
                                    <caption>4.</caption>
                                    <content styleCode="bold">Why is the ventrogluteal administration approach recommended?</content>
                                    <br/>The ventrogluteal approach into the gluteus medius muscle is recommended because it is located away from major nerves and blood vessels. A dorsogluteal approach into the gluteus maximus muscle is acceptable, if preferred by the healthcare professional. The injection should not be administered in any other site.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule " valign="top">
                              <paragraph>Manufactured for:</paragraph>
                              <paragraph>ViiV Healthcare</paragraph>
                              <paragraph>Durham, NC 27701</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Trademarks are owned by or licensed to the ViiV Healthcare group of companies.</paragraph>
                              <paragraph>©2024 ViiV Healthcare group of companies or its licensor.</paragraph>
                              <paragraph>APR:5IFU</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>This Instructions for Use has been approved by the U.S. Food and Drug Administration.             Revised: 9/2024</item>
                  </list>
               </text>
               <effectiveTime value="20240920"/>
               <component>
                  <observationMedia ID="AE46A390-5BED-4676-8B4F-5CD01EF822C8">
                     <text>Instructions for Use header</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_1d73cff2-e068-480a-a7ad-9dc4de9762ed">
                     <text>storage information</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_46a94cca-40db-44f2-a120-16f2a110d44f">
                     <text>Kit contents</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_2e73283f-fd90-4d22-9050-41d58e690bb9">
                     <text>Figure A</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_3c56771c-f1b0-43d1-9f84-3d0f5e770300">
                     <text>Figure B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_5f40754e-cbff-4a51-b818-ad0cc9a9d6bf">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_54360fae-fb0e-4b7a-a1e0-d3190a4c9057">
                     <text>Figure D</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="AB9CD7CB-81B6-45E1-B158-BE8D9F23E338">
                     <text>Figure E</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_17e78c2d-b1ed-48cc-9ceb-ba8aac49f39e">
                     <text>Figure F</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_399c6b03-640e-4b95-bbed-887501e7f76d">
                     <text>Figure G</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_646d1857-31a6-4d6a-86e0-f9c11be967e8">
                     <text>Figure H</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="AC7C48A7-671F-4302-B1F5-13C2483A566E">
                     <text>Figure I</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="E7B0D59D-E89B-4652-9FD7-5AA410703AC4">
                     <text>Figure J</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_8ce9bb92-c57f-40cb-a42b-ddd486bc5174">
                     <text>Figure K</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_142efe88-ec6b-43a5-9bad-89d2cd7c8005">
                     <text>Figure L</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_5ee44e9e-4275-4db8-82ba-53a426eaa8c7">
                     <text>Figure M</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="B144C58F-EC4E-4C7F-A762-949B92E8986A">
                     <text>Figure N</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="BF84167A-96D2-4AE7-8B46-21D2F4D2F029">
                     <text>Figure O</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_4d09a3d0-3080-4ac8-9540-50d24af19a3e">
                     <text>Figure P</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_13ccf563-323b-435b-9302-66e9b34ce64f">
                     <text>Figure Q</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="F59CFF8C-3C17-4218-8949-276667545FC7">
                     <text>Figure R</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_44979507-6ee4-449f-b4a7-dad655ef3e4e">
                     <text>Figure S</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DE9628A5-E2A2-45C4-B8D6-C0E64A1BC1D5">
                     <text>Figure T</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="BAF69D69-033A-4E01-955D-76192A35EDB1">
                     <text>Figure U</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="BD95C5A6-DA23-469D-A2FC-2CEC0FB9089C">
                     <text>Figure V</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_5513cc9c-5b5c-4600-885f-21f3f54d61a4">
                     <text>Figure W</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cc3cb7b7-6964-4dcf-9bc0-b663065f2ab8">
               <id root="8d32638c-17d7-4154-bd1d-4c68103e7b7b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 49702-264-23</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Apretude</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(cabotegravir extended-release injectable suspension)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">600 mg/3 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(200 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For gluteal intramuscular use only.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Healthcare Professional Administration Only.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Contents:</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Single-dose vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Vial adapter</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Injection needle (23 gauge, 1 ½ inch)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Prescribing Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patient Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ensure vial adapter is used correctly.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ViiV Healthcare</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">600 mg/ 3 mL Kit</content>
                  </paragraph>
                  <paragraph>Made in Singapore and Belgium</paragraph>
                  <paragraph>Rev. 2/24</paragraph>
                  <paragraph>©2024 ViiV Healthcare group of companies or its licensor.  </paragraph>
                  <paragraph>62000000092471</paragraph>
                  <renderMultiMedia ID="id-123845017" referencedObject="ID_421f19ed-3728-4608-be4a-743dd07b70d5"/>
               </text>
               <effectiveTime value="20240920"/>
               <component>
                  <observationMedia ID="ID_421f19ed-3728-4608-be4a-743dd07b70d5">
                     <text>Apretude 3 mL kit carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_baaf1170-7620-418c-8666-79632c884cef">
               <id root="91b44cf6-4480-433a-878a-58c05a118232"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 49702-280-63</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Apretude</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(cabotegravir extended-release injectable suspension)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">600 mg/3 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(200 mg/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sample-Not for Sale</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For gluteal intramuscular use only.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Healthcare Professional Administration Only.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Contents:</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Single-dose vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Vial adapter</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 Injection needle (23 gauge, 1 ½ inch)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Prescribing Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patient Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ensure vial adapter is used correctly.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ViiV Healthcare</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">600 mg/ 3 mL Kit</content>
                  </paragraph>
                  <paragraph>Made in Singapore and Belgium</paragraph>
                  <paragraph>Rev. 5/24</paragraph>
                  <paragraph>©2024 ViiV Healthcare group of companies or its licensor.  </paragraph>
                  <paragraph>62000000094179</paragraph>
                  <renderMultiMedia ID="id-1974902858" referencedObject="ID_94288192-8d58-4d6b-8e7c-f1ffe9f8e142"/>
               </text>
               <effectiveTime value="20240920"/>
               <component>
                  <observationMedia ID="ID_94288192-8d58-4d6b-8e7c-f1ffe9f8e142">
                     <text>Apretude 3 mL kit carton sample</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="apretude-spl-graphic-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>